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CHAPTER 1 
INTRODUCTION 
INTRQPIJÇTIQN 
During the last decades the conventional methods for cancer treatment have 
been Improved, but still toxic effects on non-tumour tissues, temporarily as 
well as Irreversibly, cannot be avoided with the use of radiotherapy and 
chemotherapy. Immunotherapy may be an alternative approach. 
Immunotherapy 
The hybrldoma technology. Introduced by Kohier and Mlllsteln [19], offers 
the possibility to obtain Immortalized B-cells, producing monoclonal antibodies 
of predefined specificity. Such antibodies, if directed specifically against 
tumourcelis, can be exploited for the elimination of the malignant cells without 
any deleterious side effects to non-tumour tissues. 
Production of tumour-speclflc antibodies requires the existence of tumour-
speclflc antigens. Putative "tumour-speclflc" antigens so far have turned 
out to be present on normal cells as well. These antigens appeared to be 
"cell-lineage specific" or "cell-stage specific" or they appeared to be 
expressed In very low amounts on normal cells, like the gp 95, Initially 
Identified as a melanoma-specific antigen and later on detected on all human 
cell lines tested [3,5]. Tumourcelis may differ In the expression of cell-surface 
antigens from normal cells, but so far these antigens have not been proven 
to be tumour-speclflc. The Immune-system of most tumour-bearing Individuals 
do recognize autologous tumourcelis resulting In a tumour-speclflc Im-
muneresponse [27]. Therefore the existence of tumour-speclflc antigens Is still 
possible. On the other hand abnormalities In quantitative expression of 
otherwise functional antigens, expressed by the tumourcelis, may be respon-
sible for such responses. 
Trials with Immunotherapy, using MoAb's which are not tumour-speclflc, have 
been reported on, with promising results for lymphoid malignancies [4,8,23-
,24,26,28,31], gastrointestinal adenocarcinomas [6,36], melanomas [16] and 
pancreatic cancers [35]. 
The idlotype, tumour-speclflc determinants on B-cell mallgnapcles. 
B-cells, responsible for the specific production of antibodies can give rise to 
tumours arrested at any stage of differentiation. Phenotyplcally the tumouΓ­
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Table 1. The phenotype of malignant B-cells related to their normal B-cell counterparts [2,9,10,13,31]. 
B-ALL: B-cell acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; PLL: pro lymphocytic 
leukemia; HCL: hairy cell leukemia; MM: multiple myeloma; NHL: non Hodgkin lymphoma; c- Ig: cytoplas­
mic I g ; s-Ig: surface I g ; TdT: terminal deoxynucleotidyl transferase. 
cells are very similar to their normal counterparts [13]. Depending on their 
phenotype and manifestation they are classified as leukemlas (chronic or 
acute) or lymphomas (poorly or well differentiated), each group with its own 
characteristics [9,30]. During development from stem-cells to Immunoglobulin 
(Ig) secreting plasma-cells, B-cells express only at certain stages of 
differentiation surface Immunoglobulins (s-Ig, Table 1). The differentiation 
Includes the development of the antlgen-speclflclty of the antibody that will 
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Figure 1. Human IgG molecule with Indications for the antigen binding site, 
Fc part (C2,C3 responsible for the triggering of biological activities), constant 
regions (C), variable domains (V determining the Idlotype), hyper variable 
regions (HVR expressing the Idlotopes), heavy chain (H) and light chain (L). 
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be secreted by the mature B-cell and ultimately the plasma-cell. This specific­
ity, the antigen binding site, Is formed by the hypervarlable regions on the 
Immunoglobulin (Figure 1). These regions express unique antigenic epitopes, 
the Idlotopes, which may be a specific am I no-acid sequence or a specific con­
formational structure, products of the protein translation of the rearranged 
Ig VL- and VH- chain germllne-genes [1] of each Individual B-cell. Once the 
rearrangement, has occurred, the offspring of each B-cell, can be considered 
as a clone with clone-specific Idlotopes. The Idlotope combination of a 
particular B-cell clone constitutes the clone-specific Idlotype. The specificity 
of the antigen binding site Is determined by one Idlotope or a combination of 
Idlotopes. Ig's with antlgen-blndlng sites for a specific Idlotype are called 
antl-ldlotyplc antibodies. These antl-ldlotyplc antibodies (antl-ld), may play 
an Important role In the regulation of the Immuneresponse [17]. In general B-
cell malignancies have been proven to be monoclonal, i.e. arisen from a single 
precursor cell [7,21,32]. Therefore the s-Ig* B-cell tumours express antigenic 
structures, that can be considered as truly tumour-specific, the Idlotopes. 
From 1977 on promising reports appeared on the experiences with anti­
idiotype therapy In animals [15,20,38]. In 1980 the first report appeared on 
the experiences with antl-ldlotyplc antibodies, raised In sheep. In a human 
with B-CLL [14]. In 1982, Miller et al [25] reported on the complete remission 
of a B-cell lymphoma Induced by Immunotherapy with mouse monoclonal antl-
ldlotyplc antibodies (MoAb antl-ld). These reports proved that antl-ldlotyplc 
antibodies could be potentially tumour-specific therapeutic agents In the 
treatment of B-cell malignancies. 
Although these reports are very promising, many obstacles are being en­
countered during Immunotherapy with MoAb's: 
Circulating antigen. Most s-Ig* malignant B-cells are capable to produce Ig 
and considerable id concentrations have been detected In the sera of patients 
with B-cell malignancies [37]. These Idlotype levels may form substantial 
barriers for antl-ld therapy [23,26] and the Id antl-ld Immune complexes (1С) 
may cause clinical side effects like serumslckness. 
Antigen modulation. The quantity of target antigens on the tumourcells 
determines directly the amount of antibodies that can bind to the cells 
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(opsonization). The Ig-Fc parts of the opsonizing MoAb's are responsible for 
the triggering of the tumourlcldal activities by the effector systems. Antibody 
Induced modulation resulting In decreased antigen expression reduces the 
strength of Interaction between target cells and the effector cells. Rltz et al 
[31] described an Ineffective Immunotherapy with a MoAb antl-CALLA, that 
could be explained by the In vitro finding that the MoAb antl-CALLA caused 
antigen modulation resulting In tumourcells completely lacking the target 
antigens [27]. Strong antigen modulation, resulting In upto 90X reduction of 
the 65 kD antigen on tumourcells, was observed during Immunotherapy with 
MoAb TI01 [4,33]. 
Signal transduction. Like normal B-cells tumour B-cells may respond to antl-
Ig, which may result In enhanced proliferation and Ig production [40] or In 
Inhibition of proliferation [20]. In vivo the antl-ld may be seen by the tumour 
B-cell as the natural antigen, which can result In actl- vatlon, proliferation, 
differentiation or down regulation depending on multiple factors, like for 
Instance the presence of growth- and differentiation factors. Therefore the, 
In vivo, responses of B-cell tumours to MoAb antl-ld may affect the therapeu-
tical outcome of anti-id therapy. 
Mouse Ig Isotype. Kamlnsky et al [18] demonstrated, In a mouse model, that 
the Isotype of the MoAb antl-ld used for therapy also determines the 
therapeutic effect. Using mouse MoAb's for therapy In man, the question 
raises whether one mouse subclass Is more effective than another. In fact, 
within the Caucasian population the monocytes of only 70« of the people are 
capable to Induce mouse MoAb IgG^ antl-CD3 Induced T-cell proliferation, for 
mouse IgGjj/IgGj this Is ±100* and for IgQ^, It Is less than 10X [39]. The 
differences In response to these different subclasses of mouse MoAb antl-CD3 
are ascribed the Fc receptor polymorphism on human mono-cytes. These 
findings strongly suggest that the mouse Ig subclass used, might play a role 
in the final outcome of Immunotherapy with mouse MoAb's. 
Tumour diversity. Although It has been demonstrated that B-cell malignancies 
are mostly monoclonal [7,21,32], the simultaneous coexistence of different 
malignant B-cell clones has been described as well [11]. Besides, therapy may 
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Induce selection of mutated tumourcells, which may be generated spontane­
ously [12] or Induced by therapy [22,29]. A mutation within the Idlotype may 
result In the loss of binding of the MoAb ant I-Id to the Idlotype mutant. 
Tumourcells expressing the Idlotype mutant may escape from therapy. 
Anti-mouse response. Problems very similar to those Introduced by circulating 
antigen are the development of antibody responses to mouse Ig. The 
appearance of these antibodies will abolish further effective therapy with 
MoAb's [7,24,34,35]. 
The alms of this study were: 
1) The treatment of patients with B-cell lymphomas or leukemlas with MoAb 
antl-ld. 
2) The analysis of the biological responses that are triggered by the 
Interaction with MoAb antl-ld. 
3) The determination of parameters that are essential for the clinical outcome 
of Immunotherapy with MoAb antl-ld. 
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Treatment of chronic lymphocytic leukaemia with monoclonal anti-idiotypic 
antibody 
Г J A CAPFI , F W Μ В PREIJLRS*, W A ALLtBES and С 
Summary 
A patient with chronic lymphocytic leukaemia (CLL) 
was treated with a monoclonal antibody directed 
agami! the idiolvpe present on the surface immuno­
globulin of the B-CLL cells Administration of 
antibody resulted in the first instance in clearance of 
large amounts of circulating free idiotype and, there­
after, m antibody binding to the tumour cells At this 
stage of therapy marked tumour reduction was 
observed During the various courses of treatment, 
therapy resistance developed due to antigenic modu­
lation and an inefficient natural effector mechanism 
This therap\ induced no serum sickness but, when 
tumour cells were destroyed, pulmonary distress 
developed which was dependent on the rate of 
antibody administration and could be reversed by 
means of an antihistamine This study shows that, 
although no long-lasting clinical improvement was 
obtained, monoclonal anti-idiotypic antibody thera­
py is m principle effective even in the presence of large 
amounts of circulating antigen The induction of 
therapy resistance by antigenic modulation was most 
likely related to the clearance rate of antibody-coated 
cells ¡he overall capacity of the natural effector 
mechanism therefore exerts an important influence on 
the outcome of antibody therapy Neth J Med 
1985,28 112 
Introduction 
Treatment of malignancies with monoclonal anti-
bodies is a recent development in tumour therapy 
Due to the current lack of antigens which are truly 
tumour-specific, differentiation antigens present on 
tumour cells arc commonly used as target antigens 
for monoclonal antibodv therapy' Neoplastic B-
lymphocytes, which are the result of proliferation of 
single cell clones2 ', express on their cell membrane 
surface immunoglobulins which contain the same 
variable antigen-binding domain, the idiotype The 
idiotype can therefore be considered a tumour-
specific marker for B-cell malignancies Polyclonal 
anti-idiotypic antibodies have been used in the 
treatment of В leukaemias in animal models4 ' and in 
Departments of Nephrology and *Haematology St Radboud 
Nijmegen 
HAANFN* 
man
78
, and proved to be only partially effective 
Treatment of a follicular lymphoma with a mono­
clonal anti idiotypic antibody resulted in induction 
of a complete remission', however, in other cases 
this type of therapy was only partially effective (R 
I cvy, personal communication) In studies with 
monoclonal antibodies directed against differentia­
tion antigens, idiotypes as well as other tumour-
associated antigens, only a modest clinical result was 
achieved in most cases This was due to a series of 
factors leading to therapy resistance, such as circu­
lating antigens, antigenic modulation, immune 
response to murine antibodies and inefficiency of 
natural effector mechanisms Here we describe 
treatment of a B-CLL patient with a monoclonal 
anti-idiotypic antibody This therapy was initially 
effective and resulted in significant tumour reduc­
tion However, in the course of therapy resistance 
developed due to antigenic modulation and msuffi-
uency of the natural effector mechanism 
Patient and methods 
Patient 
The patient, a male born in 1931, was diagnosed in 
May 1973 as having CLL He presented with 
enlarged axillary lymph nodes and tonsils and 
splenomegaly of 4 cm below the costal margin The 
leucocyte count was 40x10'/! with 85 per cen,t 
lymphocytes During the following year slow pro­
gression was observed, and from December 1974 on 
inlermiltent therapy with 10 mg chlorambucil per 
day was given The good initial response to this 
treatment gradually decreased and in October 1982 
chlorambucil treatment became ineffective In May 
1983 the leucocyte count was 180X lo'/l with 99 per 
cent lymphocytes which were positive for κ chain, 
and the heavy chain expression was predominantly γ 
but also μ, δ, α There was marked splenomegaly 
and hepatomegaly Local irradiation of the spleen 
was therefore applied to a total dose of 3 4 Ογ At 
the onset of anli-idiotype therapy, the'leucocyte 
count was 24x10'/!, the spleen was palpable 15 cm 
Hospital University of Nijmegen, P O Box 9101, 6500 HB 
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and the liver 4 cm below the costal margin Lymph 
nodes in the cervical, axillary and inguinal regions 
were enlarged and had a diameter ranging from 2 to 4 
cm The concentration of circulating free idiotype 
was 100 μ§/πιΙ 
Monoclonal anli-tdiolypic antibody 
BALB/c mice were immunized ι ρ with io7 B-CII 
cells suspended in complete Freund adjuvant After 
three weeks the animals were boosted 1 ν with io' 
B-CLL cells on three consecutive days On day 25 
the spleen cells were fused with the cell line Sp 2/0 in 
the presence of polyethylene glycol 1500'° To screen 
antibody production, an enzyme-linked immunosor­
bent assay (ELISA) with B-CLL cells coated to 
polystyrene microtitre plates was used as previously 
described" Parallel to this screening the B-cell lines 
RPMI 1788, CCRF-SB and B-CLL cells from a 
different patient were used Clones which were only 
reactive with the B-CLL cells of the patient were 
further analysed using cells of HLA-identical rela­
tives and a I-cell line of the patient which was 
established by cultunng peripheral leucocytes in the 
presence of phytohaemagglutinin and mterleukin 2 
The remaining clones, which were not reactive with 
this panel of cells but only with the patient's В CLL 
cells, were then tested for reactivity to human Ig with 
the same allotype Of 1504 clones, 1 clone positive 
for B-CLL cells was negative in all other tests and the 
anti-idiotypic nature of the monoclonal antibody was 
confirmed by co-capping with anti-human Ig anti­
bodies and inhibition of binding with the patient's 
free circulating idiotype 
Purification of monoclonal anti-idiotypic antibodies 
In specific pathogen-free BALB/c mice, ascites was 
induced by 1 ρ injection of г х ю " hybridoma cells 
one week after injection of pnstane Immediately 
after collection the ascites was heat-inactivated at 
560C for 40 minutes The isoelectric point of the 
IgGi anti-idiotypic antibody was 6 2 and it was 
therefore precipitated with ammonium sulphate at a 
final concentration of 60% The precipitate was 
dissolved in PBS, dialyscd against о 01 M sodium 
phosphate buffer pH 6 о and applied to a DEAL 
cellulose column (Whatman) equilibrated with ο οι 
M sodium phosphate buffer pH 6 о The unbound 
protein which contained the anti-idiotypic antibody 
was dialysed against PBS and concentrated to 10 
mg/ml The whole procedure was carried out under 
sterile conditions and the final product was ultracen-
trifuged in a SW 35 rotor for 45 minutes at 35000 rpm 
and then twice sterilized by о 2 μ filtration After 
testing for sterility and the presence of pyrogens 
NethJMed28(l985) 
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using ι v injection in rabbits, the antibodies were 
stored at 4°C A total of 40 g antibody was puri­
fied 
Determination of free circulating idiol\pe 
A dilution series of the patient scrum or plasma was 
incubated with different fixed concentrations of 
anti idiotypic antibodies After 30 minutes the 
remaining activity of anti-idiotypic antibodies was 
determined in an ELISA using coated B-C 1 1 cells as 
described above The serum concentration which 
could block the entire anti-idiotvpe activitv was 
determined and the concentration of free idiotvpc 
was expressed as equivalent of the amount of μg 
antibody blocked by 1 ml scrum 
Determination of free anti-idiotvpe 
The concentration of free anti-idiotypc in serum was 
measured by ELISA as described above using a 
dilution series of serum The concentration of 
antibody was calculated using various standard 
concentrations of anti-idiotype antibody in the same 
assay 
Determination of cell-bound idiotvpe and ami idio 
type 
Lymphocytes were purified from 5 ml blood samples 
by Ficoll-Isopaque (Pharmacia) centrifugation with 
a density of 1 077 To determine the amount of cell 
surface idiotype, s χ io' lymphocytes were incubated 
with 1/200 diluted anti-idiotype (10 mg/ml) for 30 
minutes at room temperature and after washing 
three times ιοομΐ i/ioodiluledriTC-labclled sheep 
anti-mouse Ig antibodies (Cappel) was incubated for 
30 minutes followed, after three washings, by incu­
bation with 100 μΐ i/ioo diluted I ITC-labelled burro 
anti sheep Ig antibodies (Kallestad) After washing 
three times the fluorescence was analysed flow-
cytometrically using an Ortho H30 cytofluorograph 
The amount of anti-idiotype bound in vivo was 
determined in a similar way, omitting the first 
incubation with anti-idiotype 
Clearance of '''Cr-labelled, anti-Rhl) coated erythro 
cytes 
From 10 ml blood the erythrocytes were labelled 
with 50 μΟ sodium Chromate (Amcrsham), after 
washing three times with «50 ml PBS, 5 ml packed 
crjthrocvtes were incubated with 10 ml 1/2 diluted 
human anli-RhD IgG antibodies (Merz and Dade) 
for 30 minutes at room temperature After washing 
three times with 50 ml PBS the cells were suspended 
in an end-volume of 10 ml and injected 1 ν At 
various time intervals 3 ml samples of blood were 
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counted in an LKB γ counter An RhD-positive 
healthy volunteer served as control and received 
coated autologous erythrocytes 
Results 
Anti idiotypic therapy 
Therapy with monoclonal anti-idiotypic antibodies 
was started in June 1984 by ι ν infusion of 5 mg 
antibody supplemented with 2 mg clemastine and 25 
mg prednisone as prophylaxis The leucocyte count 
was 24 x IO'/I and splenomegaly of 15 cm and 
hepatomegaly of 4 cm below the costal margin was 
present All lymph nodes were enlarged and had a 
diameter ranging from 2 to 4 cm The dose of 
antibody was increased to 20 mg and 100 mg on the 
following days On day 4 the prophylaxis with 
clemastine and prednisone was omitted and anti­
body infusion alone showed no signs of side effects 
The level of circulating free idiotype, which was 
associated for 90 per cent with i9Sandfor lopercent 
with 7S IgG antibodies, gradually decreased from 
the original concentration of 100 μg/ml With differ­
ent dosages of antibody, as indicated in fig 1 the 
free idiotypc was cleared on day 9 At that lime 
pharyngeal oedema developed which was reversed 
by administration of 2 mg clemastine and 25 mg 
prednisone From then on this prophylaxis was 
maintained during this treatment period The circu­
lating free idiotype was rapidly re-synthesized and, 
during the different courses of therapy the daily 
synthesis of secreted antibodies remained constant 
and amounted to a total of 150 mg/day When 700 mg 
antibody was administered on day 11, transient 
leucocytosis from гзхю"/! to ζ$ΧίοΊ\ was ob­
served The number of peripheral cells in S phase 
was determined by ethidium bromide staining and 
subsequent analysis by flow cylofluorometry and by 
Ή th\midine incorporation There was no increase 
in the number of dividing cells and the induced 
lymphocytosis coincided with a decrease in spleen 
size and the appearance of free anti-idiotypic anti­
body in the circulation During the 18 davs of 
therapy free anti-idiotypic antibody was detectable 
three times, together with antibody coated cells in 
the circulation, and concomitantly the spleen and 
lymph node sizes decreased Due to lack of antibody 
therapy was stopped after administration of a total of 
5 g antibody At that moment the leucocyte count 
was 29 χ IO'/I, the splenomegaly was decreased to 10 
cm below the costal margin and the enlarged liver 
was normalized The enlarged lymph nodes disap­
peared almost completely During therapy the hae­
moglobin concentration fluctuated between 6 0 and 
6 8 mmol/l The creatinine levels remained constant 
at a concentration of about 80 μιτιοΐ/ΐ and liver 
function remained unaltered During treatment alio-
daily dose 
400 anii idiotype 
(mg) 
10 12 14 16 18 
days ol trealmenl 
Fig 1 The effects of daily administration of vanous amounts of monoclonal anti idiotypic antibody on the level of free circulating idiotypc 
(A—A) the peripheral leucocyte count ( · — · ) and the appearance of free circulating anti idiotypic antibody ('—*) The tumour 
reduction as determined by the decrease in size of spleen liver and lymph nodes is expressed on an arbitrary scale 
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purinol was given as prophylaxis and the urate 
concentration fluctuated between о 25 and о 35 
mmol/1 In September 1983 the leucocyte count was 
82 χ IO'/I, the splenomegaly 23 cm and the hepa­
tomegaly was 5 cm below the costal margin, the 
palpable lymph nodes had a diameter which varied 
from 1 to 3 5 cm After plasma and leukaphereses a 
second therapy course with anti-idiotypic antibodies 
was given to a total dose of 10 g antibody adminis­
tered during 17 days, and as prophylaxis 2 mg 
clemastine was given daily In this period there was 
marked leucocytosis from 52 x to'/l to 130 x io'/I in 
1 day which decreased in two days to 35 x 10 /1 No 
dividing cells were detectable in this period This 
leucocytosis appeared when free anti-idiotypic anti­
body was detectable and coincided with a modest 
decrease in spleen size 
In October 1983 splenectomy was performed The 
spleen weighed 3700 g and contained predominantly 
idiotype-positive CLL cells At the end of October 
1983 a third therapy course with anti-idiotypic 
antibodies was applied, to a total of 5 5 g antibody 
given in 14 days Although free anti-idiotypic anti­
body was detectable in this period, no leucocytosis 
occurred and no effects of therapy were observed 
When CT scans made before and after therapy were 
compared, no significant difference in lymph nodes 
and liver size was detectable The creatinine levels 
remained constant at about 80 μπιοΐ/ΐ throughout 
this period and no change in liver function was 
observed 
Side effet is of anti-idiolypic treatment 
During treatment two patterns of clinical reactions 
were observed When the anti-idiotypic antibody 
was administered in the presence of free circulating 
idiotype, soluble immune complexes were formed 
The antigen expression on cells was in the order of 
magnitude of io4 molecules/cell and at a concentra­
tion of 100 Hg/ml free idiotvpe the latter was present 
at a 300-fold excess over cell-bound idiotype Indeed 
the binding of antibody was preferential to the free 
idiotvpe, and only when this was cleared was binding 
of antibodies to cells observed The complexes 
formed consisted of 19S IgM idiotype, 7S IgG 
idiotype, and murine IgGi Although mouse IgGi is 
not complement-binding, the complexed idiotype 
can fix complement, and during the clearance of free 
idiotype complement consumption occurred C3 
levels decreased from 75 to ^o mg/ ню ml C4 from 20 
togmg/ioomlandfactor В from 20 to 17 mg/100 ml, 
indicating substantial activation of the classical path­
way of complement Surprisingly, prophylaxis with 
antihistamine was not necessary in this phase of 
therapy Thrombocytopenia was also observed and, 
as shown in fig 2, the degree of thrombocytopenia 
depended on the rate of clearance of free idiotype 
No further side effects were observed when the 
circulating idiotype was cleared as long as the 
antibodies were administered 1 ν When by accident 
some antibody had leaked subcutancously, a local 
inflammatory reaction developed which lasted four 
days 
4 б 
days of Irealmenl 
Fig 2 Induction of thrombocytopenia (I 
anti idiotypic antibody administration 
days of (reatmenl 
) by the clearance of free circulating idiotype (•—A) as a function of the rate of 
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Another pattern of side reactions was observed 
when the free idiotype was cleared and antibody 
binding to the tumour cells occurred In this phase of 
therapy no complement consumption and no throm-
bocytopenia was observed, however mild pulmon-
ary oedema developed and bronchial constriction 
and pharyngeal oedema occurred, which was rever-
sible by administration of antihistamine and predni-
sone When antibody binds to cells prophylaxis with 
antihistamine is necessary and the rate of infusion 
becomes important Up to S5 mg antibody/hour was 
well tolerated, but at higher dosages the patient felt 
uncomfortable 
Atíngeme modulation 
When the tumour tells were incubated in vitro at 
47°C with anti-idiotypic antibodies and analysed 
flow-cvtomctncally at various times, the cell-bound 
idiotvpe expression decreased due to antigenic 
modulation, and after two hours no cell-bound 
idiotype was detectable anymore When after two 
hours excess of antibody was removed by washing, 
followed by further incubation of the cells re-
expression of idiotype occurred within 12 hours In 
vivo, however the modulation characteristics were 
different during the various treatments with anti 
idiotype During the first course of treatment only a 
small loss of cell-bound antigen of about 20-^0 per 
cent was manifest at the end of therapy During the 
second course the in vivo modulation was more 
pronounced and during the third course total 
modulation of the antigen occurred during the 
infusion period The cell-bound idiotype was re-
expressed overnight The in-vivo modulation corre-
lated inversely with the efficacv of therapy Therapy 
was effective only when in-vivo modulation was 
modest 
Clearance of antibod\ coaled erythrocytes 
The difference in m-vivo modulation during the 
entire therapy can be explained in two ways Either 
the fast modulating cells escape the antibody attack 
and form a new population of tumour cells, or the 
effectiveness of the clearance of antibody-coated 
cells decreases by which the circulation time of these 
cells increases When this time exceeds a two-hour 
period, the modulation process becomes complete 
The fact that the in-vitro modulation rate of all cells 
during therapy remained the same is in favour of the 
latter explanation After the third therapy course the 
capacity to clear ''Cr-labelled autologous erythro-
cytes coated with human anti-RhD IgG antibodies 
was therefore determined The results shown in fig 3 
clearly demonstrate a strongly disturbed phagocytic 
function 
% labelled erythrocyles 
hours after admmistralion of ^ Сг labelled erythrocytes 
Tig я Clearance rate of * С г labelled autologous crythroc)tes 
coated with human IgG and R h D anlihodtes in the patient at the 
end of therapy ( A — • ) in comparison with the clearance ш a 
healthy individual ( · — · ) 
Discussion 
Monoclonal anti-idiotypic antibodies can be raised 
against the idiotype of malignant B-cells and in this 
way a patient-tailored antibody can be used for 
therapy Due to the strong immunogemcity of the 
idiotype, immunization with entire tumour cells 
leads to a sufficient anti idiotype response suitable 
for hybridization techniques Screening procedures 
for detection of anti-idiotypic antibodies have now 
been improved, resulting in a one-step screening 
method, and the production of large quantities of 
monoclonal antibodies is a rapidly developing field 
Consequently technical aspects of producing individ­
ual antibodies for each patient are no longer a major 
problem for this type of antibody therapy The 
shortcomings of such therapy he in the escape of 
tumour cells from the antibody attack 
Tumour elimination by serotherapy is an Fc-
dependent process1' and the major effector mech­
anism appears to be macrophage-dependent" '' It is 
therefore of importance that human Fe receptorscan 
interact with murine Ig Recently we found polymor­
phism of human Fc receptors for murine IgGi"' l 7 
Due to this (polymorphism only 70 per cent of the 
population can bind murine IgGi The antibody 
used in this study was of the IgGi subclass and we 
therefore t) ped the patient's monocyte Fc receptors 
and found that the patient had functional Fc recep­
tors for mouse IgGi (data not shown) In principle, 
therapy with an IgGi anti-idiotypic antibody was 
effective but therapy resistance developed and no 
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long-lasting clinical improvements were achieved 
The problems encountered in this therapy were high 
levels of circulating antigen, which inhibited binding 
of antibody to tumour cells, antigenic modulation 
and an insufficient natural immune effector mech­
anism The high levels of circulating antigen could be 
reduced by administration of large quantities of 
antibody, but due to rapid re-synthesis of this 
idiotype (150 mg/day) the effect of plasmaphereses 
to reduce the concentration of idiotype was only 
small and transient, and even when the idiotype was 
cleared the daily therapeutic dose of antibody had to 
exceed 150 mg per day The problem of large 
amounts of circulating antigen could be overcome, 
and a therapeutic effect of antibody was shown in 
this case Another drawback of high levels of 
circulating antigen could be that the clearance of 
large amounts of immune complexes by the RFS 
reduces the capacity of this system to clear antibody-
coated tumour cells, which may be compared with 
the decrease in phagocytic function of SLE patients 
due to high levels of circulating complexes" 
Antigenic modulation by binding of antibodies to 
the tumour cells was completed within two hours 
when tested in vitro The in-vivo modulation showed 
different patterns Initially, it was modest but it 
increased during therapy and at the end of therapy 
the modulation in vivo showed the same kinetics as 
that in vitro Because in-vitro modulation remained 
constant during therapy, this difference in in-vivo 
modulation may be explained by an increase m 
circulation time of antibody-coated cells due to a 
decrease of phagocytic function When newly 
recruited cells in the circulation are cleared before 
modulation is complete, peripheral cells show only a 
limited loss of antigen due to antigenic modu­
lation 
That recruitment of cells from lymph nodes and 
spleen into the peripheral blood stream by antibody 
binding occurs, is suggested by the transient leuco-
cytosis which coincided with a decrease in size of 
these organs when free antibody became detectable 
Another explanation of the leucocytosis could be 
that the cells are stimulated by the binding of 
anti-idiotypic antibodies and start to proliferate 
Two observations argue against the explanation that 
the leucocytosis is a result of increased proliferation 
Firstly, there was no increase in the number of cells 
in S phase, secondly, one would expect an increase in 
lymph node and spleen size when proliferation is 
induced but the opposite was the case 
The explanation that therapy resistance was a 
result of reduced phagocytic function, is supported 
by the clearance studies with antibody-coated ery-
Neth J Med 28(1985) 
throcytes performed at the end of therapy, whether 
this function was anv better at the beginning of 
therapy is unknown But a decrease in function of 
the RES due to large amounts of immune complexes 
to be cleared and due to progression of the disease 
could explain the variation in in-vivo modulation and 
the development of therapv resistance 
An approach using cytotoxic drugs or toxins such 
as ricin A chain conjugated to monoclonal anti­
bodies, might overcome the problems of antigenic 
modulation and an insufficient natural effector 
mechanism Studies of the possible use of immuno-
toxins consisting of ricin Α-chain coupled to anli-
idiotypic antibodies are in progress 
The clinical side effects of this antibod\ therapv 
were minimal During the clearance of free idiotvpe, 
complement consumption was observed, but even in 
the absence of antihistamine there were no signs of 
serum sickness The degree of thrombocytopenia 
which developed during this stage of therapv corre­
lated with the kinetics of idiotype clearance Most 
likely this thrombocytopenia was a result of platelet 
aggregation by immune complexes When tumour 
cells were destroyed, pulmonary distress developed 
with signs of bronchial constriction and pharyngeal 
oedema These effects were reversed by administra­
tion of antihistamine and were probably caused by 
the release of various lymphokines during cell death 
When the infusion rate was below 5«; mg antibody/ 
hour, these side effects were absent 
We may conclude that monoclonal anti-idiotypic 
antibodies have therapeutic capacity in principle, 
but problems such as circulating free antigen anti­
genic modulation and lack of natural effector mech­
anisms have to be solved Treatment of patients in an 
earlier phase of disease and possible use of immu-
notoxins might result in a more effective therapeutic 
application of monoclonal antibodies 
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Summary. A patient having а В cell chronic lymphocytic 
leukaemia was treated with a monoclonal antl-idiotypic 
antibody (MoAb an ti-id) Up to 24-5 g of MoAb anti-id has 
been administered to the patient over a penod of 1 year 
without serious side effects. Despite a substantial amount of 
serum idiotype (id = I()()/ig/ml)and a low expression of id on 
the tumour cells (±h()00 тоіегміе·: per roll) clear.inre of 
serum id and a marked tumour reduction was obtained. 
Therapy resistance developed and coincided with a decreased 
clearance rate of circulating id-anti-id immune complexes 
and an increased modulation of cellular id expression, m vivo. 
Human B-cell malignancies are supposed to be monoclonal 
(Fialkow et al 1973: Levy et al, 1977) and if cell surface 
immunoglobulin is expressed, the id j о type (the anLigen 
binding side) can be considered as a tumour specific marker. 
Therefore anti-idiotypic antibodies (anti-id) might have 
therapeutical advantages in tumour therapy One complete 
remission (Miller et a). 1982), several partial remissions 
(Meeker et al 1985b, Capel et al. 1985), and some therapy 
failures (Hamblin et al 1980. Meeker et al, 1985b, Rankin ci 
al, 1985) have been reported The fact that one complete 
remission has been achieved in a patient with advanced stage 
of disease, resistant to conventional therapies, shows the 
potential of this kind of therapy However, the major 
mechanisms by which tumour regression is induced and the 
various ways in which resistance to therapy may develop 
must be elucidated before this type of therapy can become 
more generally applicable 
Correspondence Dr Wíl A Allebes. Department of Nephrology. 
University Hospital. РОВ 9101. 6500 HB Nijmegen. The Nether­
lands 
This suggests that a decreased clearance rate of anti-id coated 
tumour cells provided more time for id modulation in vivo. 
resulting in therapy resistance Therefore, the overall capa­
city of the natural effector system may have an important 
influence on the ultimate therapeutic effect of immuno­
therapy with MoAb anti-id Although the partial remission 
obtained was not long-lasting this study shows that MoAb 
anti-id therapy can be effective even when id expression on 
the tumour cells is low and a substantial amount of serum id 
is present. 
MATERIALS AND METHODS 
Pflíiení In 197Î B-cell chronic lymphocytic leukaemia (B-
CLL) was diagnosed in a man born in 1931. Intermittent 
chemotherapy (chlorambucil 10 mg/d) was given, but 
resistance to therapy developed gradually. In 1983, at the 
onset of anti-id therapy, the leucocyte count was 27x10'/ l . 
the spleen reached 15 cm and the liver 4 cm below the coastal 
margin Lymph nodes in the cervical, axillary, and inguinal 
regions were enlarged, with diameters ranging from 2 to 4 
cm A bone marrow aspirate showed that 90% of the 
nucleated cells were lymphocytes. 
Preparation of MoAb anli-id The MoAb anti-id preparation 
has been described previously (Capei et al 1985) Briefly, 
В A LB'с mice were immunized with B-CLL cells. Fusion was 
performed as described by Kohier & Milstein (1975) Anti-id 
reactivity was tested in several assays* an enzyme-linked 
immunosorbent assay (ELISA Tax et al 1984b) with id+ or 
id- cells or with human immunoglobulins, an indirect 
immunofluorescence assay (IF) on tumour cells of several B-
CLL patients. B-cell lines. HLA-identical B- and T-cells and 
autologous T-cells. monocytes, granulocytes, red blood cells 
and platelets; and an indirect immunoperoxidase assay on 
frozen tissue sections of lymphoid and non-lymphoid ongin. 
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Further confirmation of the anti idiotypic nature of MoAb 
antl-id was obtained by co-capping studies with anti-human 
Ig antibodies and by binding inhibition studies with the 
patient s idT scrum and with id control serum 
Protein from ascitic fluid containing the IgGi МоЛЬ anti-id 
was precipitated and punfied by column chromatography 
(DRAB-S2 Whdtman Ltd. Maidstone UK) Finally МоЛЬ 
an ti-id was ul traeen tnfuged for clearance of insoluble 
particles sterilized by 0 2 ¿¿m filtration and tested for sterility. 
absence of viral contamination and pyrogens 
Anti-id adrmnistraUon Four anti-id therapy sessions were 
performed in a year with each session lasting for about 3 
weeks Antibody infusions were given daily or continuously 
They were supplemented by 2 mg clemastine per day and in 
the lirst session 2 5 mg prednisone per day was given on days 
1-4 as prophylaxis against anaphylactic reactions to the 
anti-id Pnor to and during therapy physical biochemical 
hacmatological and immunological parameters were 
examined 
/ ree serum id and anti-id Serial dilutions of the patient's 
serum were pre-incubdted with different concentrations of 
MoAbanti-id The remaining anti id activity was determined 
in ELISA on B-CLL cells of the patient (Tax ci al 1984b). using 
a double layer of peroxidase (PO) conjugates, rabbit anti-
mouse Ig PO and goat anti-rabbit Ig PO (Miles Labo raton es 
Im Calif) ГшаІІу freshly prepared substrate was added 
(0 8 mg/ml 5' .immosdlrcylic dud dissolved m 50 т м 
phosphate buffer, pH 6 0 contaming 0 8 μΐ/ml 30% Н
г
02) 
After 30 mm the signal was measured at 4 50 nm on и 
litcrtck multiskan The highest serum dilution that blocked 
the anli-id activity completely was determined The serum id 
concentration was calculated in equivalents of MoAb ant I-id 
lhal was neutralized by 1 ml of serum bree serum anti-id was 
determined in .in F,I ISA of serial dilutions of serum as 
described above and compared with standard concentra­
tions of anti-id 
¡d-anti-td immune complexes The total amount of circulat-
ing dnti-id mouse Igii] was determined by radial immuno-
diflusion using anti id as standard The amount of id-anti-id 
immunecomplcxes (1С) was determined by subtracting the 
amount of free serum anti-id determined in FI ISA as 
described above from the total amount of mouse IgCj From 
the Mancini IgCïi values determined in scrum obtained the 
day before and the day after anti-id infusion the clearance 
rate of the id-anti-id 1С and the half life value (Γι ) in hours 
was calculated Id-anti-id (1С) in sera were analysed by 
isokinetic sucrose gradient fractionation (Faaber el Ы 1985) 
hach fraction was examined in an ELISA, with goat anti-
mouse Ig (Cappel, West Chester Pa ) Human Ig was 
demonstrated by peroxidase labelled human Ig isotype 
specific antisera (Dakopatts Denmark) mouse Ig by peroxi­
dase labelled mouse Ig specific antiserum (Miles) 
¡d expression and tumour celi bound anti-id Mononuclear 
cells were isolated from blood by bicoll-Hypaquc (rf- 1 077 
g/ml Phdrmaud) density centnfugation Id expression was 
determined by immunofluorescence by incubation of cells 
with MoAb anti-id and a double layer of ГІТС conjugates 
(sheep anti-mouse Ig Cappel burro anti sheep Ig Kallestadt, 
Chaska. Minn ) Cell bound anti-id (m vivo) was determined in 
a similar way omitting anti-Id Immunofluorescence on 
tumour cells with rabbit antisera, specific for human IgM 
IgC IgD IgA IgE. kappa or lambda light chain (Central 
Laboratory of the Netherlands Red Cross Blood Transfusion 
Servite (CLB). Amsterdam The Netherlands), in combination 
with a double layer FITC conjugates (goat anti-rabbit lg. 
rabbit anti-goat lg Kallestadt) was used to determine isotypc 
and light chain expression Samples were analysed by flow 
cytometry 
Proliferation assay B-CIJ, cells (2 χ 1 OVwell) suspended in 
RPMI 1640 (DM Flow I-ab s Ine , In gl e wood. Calif ) supple­
mented with 2 т м L-glutamine. 1 т м pyruvate. 50 μΜ β-
mercapto-cthanol, 5% w/v gcntamicin and 5% heat Inacti­
vated fetal calf serum (FCS) were incubated with different 
concentrations of MoAb anti-id in the presence or absence of 
10% В cell growth factor (BCGF Cellular Products Inc. 
Buffalo Ν Y ) Monocytes, obtained by adherence (2 5 χ 10* 
mononuclear cells/well) to U-bottom microtitre plates were 
supplemented with 10' punned allogeneic Τ cells/well and 
cocultured with IgÜ, or IgGj, antl CD3 MoAbs (0 5 μg/ml) 
Triplicate cultures were incubated in 9 6-well microtitre 
plates (Flow) at 370C. 5% COj in air and 100% relative 
humidity for 48 h. followed by 24 h with 0 5 μΟ 'H-
thymidine per well (Amersham) The cultures were har­
vested and radioactivity was counted 
Clearance of "Cr ìabeììed anti-RhD coated erythrocytes 
Krythrocytes were labelled with 50 μΟ Na^'CrO* (Amer­
sham Γ К ) After washings 5 ml packed erythrocytes were 
incubated with 10 ml 50% diluted human IgG antl-RhD 
antibodies (Men and Dade Dudlngen Switzerland) for 30 
mm at room temperature After washing, the cells were 
suspended in a final volume of 10 ml and injected ι ν At 
various time intervals blood samples were taken and 
counted A RhD positive healthy volunteer, who received 
coated autologous erythrocytes, served as control The 
clearance rate was determined and the value of the half life 
value (Γι) was calculated 
RESULTS 
Tumour characteristics 
The patient s tumour cells were Ig positive and expressed the 
kappa light chain indicating a clonal origin About 6000 id 
molecules were expressed per cell The tumour showed a 
heterogeneity in isotype expression The majority of cells 
were μγδ *, besides cells were detected with α in combination 
with μ or γ This pattern of multiple isotype expression was 
also present on tumour cells from lymph nodes and spleen 
Multiple isotypic idiotypes were also detected by ELISA in the 
serum IgM id and IgD id were dominant but Ig(i id and IgA id 
were detectable as well The daily id production in vivo was 
calculated from the reappearance rate of id dfter the clear­
ance bv anti-id administration and ranged throughout the 
treatment period from 100 to 1 50 mg/d 
Anti-id administration 
In Fig 1 data are summarized on serum id, serum anti id and 
id-anti-id 1С On day 1 of the first therapy session serum id 
concentration was 100 μg/ml Anti-id administration 
30 
ípg/rrt\ · - · о 
200 
Anti-id Antibodies in B-CLL 
Daily dose anti-idiotype (mg • ) 
-••••D απ 
-
^ - # · A Therapy session 1 
-^^Oc^tò. 
IDDDDünDDDaaQD^ D D D ™ 
12 U 16 1Θ 
Day of therapy 
Fig 1 Id anti-id and id-antl Id 1С levels dur ing various anti id therapy sessions ( · ) Free serum id ( Δ ) Ггсе scrum anti-rd (O) id-anti-id 1С 
(A) Total dose anti-id 4 95 g strong tumour reduction (H) total dose anti id 11 52 g minor tumour redui l ion (C) total dose ant i id 5 Ь g no 
tumour reduction (D) total dose anti-td 2 42 g no tumour reduction 
cleared serum id but despite increased doses of anti-id, free 
serum id reappeared rapidly after each anti id administra­
tion The anti-id infusion rate was gradually increased up to 
80mg/h with a total dose of 700 mg/d After 11 d (total dose 
anti-id 2205 mg) free anti-id and anti-Id opsonized tumour 
cells were observed The size of the spleen decreased from 15 
to 10 cm below the costal margin, and liver and lymph nodes 
were normalized This tumour reduction coincided with a 
transient leucocytosis (day 11 24 χ 1OVI day 12 52 ж 1 О*/ 
I. day 13 38 ж 1070 'H-thymidine incorporation and S 
phase analysis of peripheral cells remained unchanged, 
suggesting an altered compartment al distribution rather 
than an increase of tumour mass by anti-id induced tumour 
cell proliferation At the end of this therapy session the total 
dose of anti id given was 4950 mg Three months later the 
spleen had enlarged to 2 3 cm and the liver to 5 cm below the 
coastal margin the lymph node diameters ranged from 1 to 
3 5cm the leucocyte count had increased to 82 χ 1071(98% 
id* lymphocytes) and the serum contained 120 /ig/ml id 
Anti-id was given continuously, in the supposition that once 
the serum id had been cleared, tumour cells might be 
opsonized and eliminated dunng a longer period of time At 
day 6 free anti-id was detected Λ modest reduction in spleen 
size was observed again coinciding with a transient leucocy­
tosis (day 6 53 8 ж 1071. day 8 130x1071. day 10 
36 4 χ 1071) Further anti-td administration up to 11 520 
mg. did not result in further tumour reduction Two additio­
nal anti-id therapy sessions, after removal of the spleen 
(weight 3700 g ±95% id cells) were also ineffective The 
patient received a total of 24 490 mg anti-id over a period of 
one year without serious side effects 
Circulatlnq immunecompiexe*: 
Circulating 1С were cleared completely overnight during the 
first therapy session and less efficiently during the sub­
sequent therapy sessions (Fig 1 ) Anti-id appeared capable of 
forming id anti-id 1С with the patient s pre-treatment serum 
m vitro (Fig 2Л) IgM id-anli id 1С was present in serum 
obtained during therapy without detectable free anti-id (Fig 
2B) No reactivity was seen with prc-therapy serum proving 
that the reactivity in serum during therapy must be caused by 
the human-mouse ICs Free anti id activity could not be 
detected with an EUS A in this serum However, mouse IgCn 
(anti-id = IgGi) was clearly detectable, with the Mancini 
assay Therefore all anti-id as determined by Mancini should 
have been present as ICs During id clearance complement 
components C3 and C4 were reduced more than 50% and 
thrombocytopenia occurred suggesting their involvement in 
this process Thrombocytopenia was more severe when the 
infusion rate was high therefore the latter was adjusted to 
the platelet counts 
Tumour cefi td modulation m vivo and in vitro 
Tumour cell id expression dunng therapy, was compared 
with the expression at the start of each therapy session The 
relative id expressions, dunng therapy session I arid 3 are 
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Fig 2 Id-anti-id immune complexes in vitro and m vivo Coating goat 
anti mou&e Ig (gem) (Α) ( Δ ) Mouse Ig In pre anti id therapy serum 
developed with gam peroxidase (gamPO) ( · ) mouse Ig In antl Id 
developed with gamPO (O) mouse Ig In 1С after Incubation of pre 
antl Id therapy serum with anb id prior to an isokinetic sucrose 
gradient sedimentation developed with gamPO (Β) ( Δ ) Human 
к mouse 1С in pre anti id therapy serum developed with rabbit antl 
human IgMPO (гаН/іРО) (о) patient serum taken during anti-Id 
therapy without free anti id developed with гаН/іРО ( · ) the same 
therapy serum as above developed with gamPO 
shown In Fig 3 Tumour cell id expression decreased when 
free anti-id was present and returned to the initial value, 
when free anti-id had disappeared 20% of the id expression 
was lost during therapy session 1 and nearly 100% dunng 
therapy session 3 in vitro, id modulation remained constant 
dunng the entire treatment period 40% reduction of tumour 
cell Id expression after 30 mm and 8 4% after 4 h This 
modulation was Independent of the concentration of anti-id, 
added in the range from 0 5 /ig to 0 S mg/ml 
in vitro tumour cell proliferation 
¡n vttro tumour cell proliferation with or without enhance-
ment by BCGF was strongly suppressed by anti-id in 
concentrations over 100 ng/ml (Fig 4) A non-reactive MoAb 
of the same IgGi subclass did not provoke any response and 
anti-id did not affect other tumour В cells in their proliferative 
activity, proving that the suppression was tumour specific 
Monocifte Fc receptor tifpmq 
Only 70% of the human population have functional human 
FcRformunnelgGi (Tdxeia/ 1983 1984a) This patient s 
Id ι oí у pe expression 
on tumour cells (Vi) 
Fig 3 Tumour cell id modulation during antl id therapy (O) id 
modulation dunng therapy session I ( · ) id modulation during 
therapy session 1 
10 ooo-
5 0 0 0 -
. 
• 
.. 
* • - - • . . 
. 
01 I io too 
Anti- rdiotype (^jg/ml) 
Fig 4 Anti-id specific suppression of tumour cell proliferation as 
determined by Ή thymidine Incorporation Tumour cells Incubated 
with IO%BCGFandlgfí|antl-id(A) control IgC, (·)and Igüí antl-
Id without BCGF (A) 
monocytes expressed functional FcR for mouse IgGi as was 
demonstrated by the monocyte dependent Τ cell mitogenesis 
(Table I) 
Therapeutic effects in relation to tumour celi id modulation and ÏC 
i ¡earance 
Fig 5 illustrates the therapeutic effect of anti-id treatment in 
relation to modulation In vivo and to the half-life value (Tú of 
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ТаЫе f FcR typing for murine IgGi on effector cells of the patient 
by monocyte FcR dependent Τ cell mitogenesis induced with MoAb 
anü CD3 
^-thymidine incorporation by purified Τ cellst 
Type of 
acessory 
cells* 
ViaCD3 
(cpm±SD) 
у2ааСОЗ 
(cpm±SD) 
No МоАЬф 
(cpmiSD) 
None 1148±ЭЯЗ 1008±527 923 ±855 
FcRyi+ 36550*759 34621 ±554 5827±395 
FcR/i" 3519±512 38217±1167 344()±186 
Paüent 37091 ±2087 35005 ±1028 7288±461 
* Accessory cells were obtained by adherence 
ΐ Τ cells were purified from a mononuclear cell suspension of a 
FcR/i individual 
% Activity caused by the mixed lymphocyte reaction during the 
incubation period 
1С A significant tumour reduction coincided with an idiotype 
modulation less than 2%/h and а Ц of 1С less than 9 h 
Nonresponsiveness to the treatment coincided with an 
increased idiotype modulation (up to 2 5% h) and a prolonged 
Ъ
г
 for 1С (up to 37 h) The increasing Γι of 1С during anti-id 
administration indicated an exhaustion of the effector sys 
tem Recovery of the clearance capacity was established in 
the time between the therapy sessions Τι value For antibody 
coated erythrocytes was 7 d for the patient after the third 
therapy session and 4 5 min for a healthy volunteer These 
data indicate a general (not mouse IgG, specific) exhaustion 
of the effector system at the time that id-anti-id 1С were being 
cleared slowly 
DISCUSSION 
We describe a substantial tumour reduction by immuno­
therapy with MoAb anti-id Meeker et ai {1985b) observed 
that in one of their patients a single dose of anti-id resulted in 
a dramatic fall In circulating tumour cells and suggested that 
the antl-prollferative effect of MoAb anti-id might be respon­
sible Although the anti proliferative effect of this MoAb 
might have contributed to the tumour reduction in our 
patient it is most likely not the major mechanism During 
therapy we noticed that the clearance rate of 1С and the id 
expression on circulating tumour cells decreased whereas 
the anti-proliferative effect in vitro of anti-id on the tumour 
cells remained unaltered The reduced clearance rate might 
have resulted m a longer circulation time of the anti-id 
opsonized tumour cells so that modulation could occur and 
tumour cells could escape from the phagocytic system 
Because functional FcR for mouse I g d were present 
patient s effector cells were able to handle anti id opsonized 
tumour cells A general exhaustion of the effector system was 
confirmed The T« for opsonized autologous erythrocytes was 
7 d in the patient and 45 min in a healthy individual Large 
amounts of tumour cells can not be eliminated by such an 
exhausted effector system whilst tumour cells loose their id 
expression within 4 h Other escape mechanisms like id 
mutation (Raffeld et al 198 5 ) or selection for id tumour cells 
(Meeker et al 1985a) were excluded because id expression 
returned to normal in the time between the anti-id infusions 
Therefore our data suggest a dominant role for opsonuation 
followed by phagocytic elimination as the most important 
mechanism for the observed tumour reduction In our 
opinion the exhaustion of the natural effector system is the 
major cause of therapy failure In this context the splenec­
tomy performed after the second session may have had 
additional deletenous effect on the clearance capacity 
of circulating imrmnoctmplexK (h) 
4 0 -
significanf tumour reduclton 
(1) 
гтыпсг tumour reducto! 
(2) 
Idiotype loss per hour by 
circulating tumour cells (*/·) 
no fur tter tumour reduc 1юп 
ЕЗ-П Π Π 
Weeks of therapy 
Fig 5 Half life value (Γι In hours) of id-anti Id 1С in serum during vanous anti Id therapy sessions in relation to the in vivo modulation (% idiotype 
loss per hour) and tumour reduction 
33 
WH Α. Aliebes et ai 
During therapy, the serum id clearance coincided with a 
substantial complement consumption (C3, C4) and thrombo-
cytopeniu suggesting an important role for complement and 
platelets in the clearance of ICs. Although the anti-id used 
was not complement binding, the id-anti-id ICs are able to 
activate complement because of the IgM and Ig(ì id compo-
nents within the ICs. This complement activation might have 
been beneficial, because C3b prevents the formation of large 
ICs. which can deposit in tissues causing severe damage, and 
also facilitates the clearance by the macrophage system. In 
addition, platelets could have interacted with ICs by their FcR 
or Clq receptor, a carrier mechanism comparable to C3b 
opsonized, erythrocyte mediated. 1С transport as described by 
Schiffer!i PÍ al ( 1986). These mechanisms could explain why 
large amounts ofidiotype were cleared without any signs of 
1С disease, and why liver and kidney function remained 
unaltered during anti-id therapy. 
Anti-id antibodies are effective In the therapy of В cell 
malignancies, but many factors may determine the ultimate 
effect: tumour mass, the capacity of the natural effector 
system, escape mechanisms like modulation and mutation of 
the idiotype. the amount of free serum idiotype and the anti-
mouse immune response (Hamblin et ai. 1980; Gordon el al. 
1984: Meeker et al i 985a. b: Capel et al. 1985: Rankin et al. 
1985: Ra líe Id et al. 1985). The promising experiences with 
anti-id therapy by several authors, justify the treatment of 
patients at less advanced stages of disease. This might 
improve the results of treatment, due to a lower tumour load. 
lower circulating id levels, and a better condition of the 
effector system. Further improvement might be obtained by 
combination of anti-id therapy with immunomodulalory 
agents like IFNa. IFNy. ILiOrTNF. Some promising results on 
these combination therapies in mice f Bash am et al. 1986: 
Btrinstein & Levy. 1987) and in man (Brown et al. 1987) 
have been published. Further studies are needed to improve 
the utilization of Mo Abs and their anti-tumour potential. 
ACKNOWLEDCMENTS 
We thank 1)г В. К. de Pauw and Dr A. J. lloitsma for their 
stimulating support. A. II. N. Pennings for operating the 
flowcytometer. Dr F. Corstens for the erythrocyte clearance 
studies. W. Tamboer, R. Willems and R. Knops for technical 
assistance and the nursing staff of Haematology for their 
qualified help and support. 
This work was supported by the Ank van Vlissingen 
Foundation and the Dutch Foundation for Medical Research 
Mcdigon (Grant no. 900-506-036). 
REFERENCES 
Basham. T.Y.. Kaminsky. M.S.. Kitamuru. K.. Ley. R. & Merigan. T.C. 
( 19КЬ) Synergistic antitumor effect of inicrferon and antl-idlotype 
monoclonal antibody in murine lymphoma, ¡ournal of Immunology, 
Π 7, 1(ПЧ-Ш24. 
Bcriiistcln. N. & Levy. R. (1987) Treatment of a murine В cell 
lymphoma with monoclonal antibodies and ILj. ¡ournat of Immu-
mlagy. 119.971-476. 
Brown. S., Horning. S., Miller, R.. Basham, T., Merigan, T. & levy. R. 
(19N7) Combination anti-idiotype antibody and alpha interferon 
therapy of В cell lymphoma. Blood. Suppl. 1, 70. 243a. 
Capel. P.J.A.. Preijers. F.W.M.B., Allebes, W.A. & Haanen. С. (19Θ5) 
Treatment of chronic lymphocytic leukaemia with monoclonal 
anti-idiotyptc antibody. Netherlands fournal of Medicine. 28, 112-
118. 
Faaber. P.. vd Broek. M.F.. Rijke. C.P.M.. Capel. P.).A. & Berden. 
J.H.M. ( 1985) Direct binding of monomeric anti-DNA antibodies lo 
RA|I cells. Scandinavian journal of Immunology. 22, 539-548. 
Flalkow. P.J., Klein. E., Klein. G. & Singh. S. ( 1973) Immunoglobulin 
and glucose-b-phosphate dehydrogenase as markers of cellular 
origin in Burkltt lymphoma, journal of Experimental Medicine. 138, 
89 102. 
Gordon, ).. Abdul-Ahod. Л.К., Hamblin. T.J.. Stevenson. F.K, & 
Stevenson. CT. ( 1984) Mechanisms of tumor cell escape encoun­
tered in treating lymphocytic leukaemia with anti-idiotyplc anti­
body. tìritish journal of Cancer, 49, S47-557. 
Hamblin. J.T., Abdul-Ahad. A.K.. Gordon, J.. Stevenson. F.K. & 
Stevenson. C.T. (1980) Preliminary experience in treating lym-
phocytic leukaemia with antibody to immunoglobulin idiotypes 
on the cell surfaces. British journal of Cancer, 42, 495-502. 
Köhler. G. & Milsteln. С. (1975) Continuous cultures of fused cells 
secreting antibody of predefined specificity. Nature, 256.495-497. 
Levy. R.. Wamke. R.. Dormán. R.F. & Halmnvlck. j. (1977) The 
monoclonality of human B-ccll lymphomas, journal of Experimen-
tal Medicine. 145, 1014-1028. 
Meeker. T. Lowder. J.. Cleary. M.L.. Stewart, S.. Wamke. R.. Sklar. J. 
& Levy. R. (1985a) Kmergence of Idiotype variants during 
treatment of B-cell lymphoma with antl-idlotypc antibodies. New 
England journal of Medicine, 312. 1658-1665. 
Meeker. T.C. Lowder, J.. Maloncy. D.C, Miller, R.A., Thlelcmans. K.. 
Wamke, R. & Levy, R. (1985b) A clinical trial of anti-idiotype 
therapy for В cell malignancies. Blood. 65, 1349-1363. 
Miller. R.A.. Maloney. D.G.. Wamke, R. & Uvy. R. ( 1982) Treatment 
of B-cell lymphoma with monoclonal anti-idlotypic antibody. New 
England journal of Medicine. 306. 517-512. 
Rancid. M.. Ncckcrs, L. Longo, D.I.. & Cossman. (. (1985) Sponta­
neous alteration of idiotype in a monoclonal B-cell lymphoma: 
escape from detection by anti-idiotype. New England journal of 
Medicine. 312, 1653 1658. 
Rankin, K.M.. Hekman. Α., Somen. R. & ten Bokkel Huinlnk. W. 
(1985) Treatment of two patients with В cell lymphoma with 
monoclonal anti-idiotype antibodies. Blood. 65, 1 373-1 381. 
Schilferli. J.. Ng. Y.C. & Peters. D.K. (1986) The role of complement 
and its receptor in the elimination of immune complexes. New 
England journal of Medicine. 315, 488-495. 
Tax. W.J.M.. Hermes. F.F.M.. Willems. R.W.. Capel, P. & Koene. 
R.A.P. (1984a) Fc receptors for mouse IgGl on human monocytes: 
polymorphism and role in antibody induced Τ cell proliferation. 
journal of Immunology. 133. 1185-1189. 
Tax. W.I.M.. Tidman. N.. Janossy. C. Trejdosiewicz. L. Willems. R.. 
leeuwenberg. ).. De Witte. TJ.M.. Capel, P.J.A. Ä Koene. RAP. 
(1984b) Monoclonal antibody (WTl) directed against a Τ cell 
surface glycoprotein: characteristics and immunosuppressive acti­
vity. Clinical and Experimental Immunology. 55. 427-436. 
Tax. W.J.M.. Willems. H.W.. Rcekerï. P.P.M.. Capel. P.J.A. & Koene. 
R.A.P. (1983) Polymorphism in mitogenic effect of IgGl mono-
clonal antibodies against Τι antigen on human Τ cells. Nature. 
λΜ. 445-447. 
34 
CHAPTER 4 
IMMUNOTHERAPY WITH MONOCLONAL ANTI-IDIOTYPIC ANTIBODIES: 
TUMOUR REDUCTION AND LYMPHOKINE PRODUCTION. 
Allebes, W.A.*, Knops, R.', Herold, M.0, 
Huber, С.0, Наап п, С.', Capel, P.J.A.+. 
DEPARTMENT OF NEPHROLOGY1, DEPARTMENT OF HEMATOLOGY*, 
UNIVERSITY HOSPITAL NIJMEGEN, DEPARTMENT OF EXPERIMENTAL 
IMMUNOLOGY*, STATE UNIVERSITY, UTRECHT, THE NETHERLANDS 
AND THE DEPARTMENT OF INTERNAL MEDICINE0, UNIVERSITY OF 
INNSBRUCK, AUSTRIA. 
Submitted for publication, 1989. 
35 
ABSTRACT 
A patient with a B-cell chronic lymphocytic leukemia was treated with a 
murine IgQ, monoclonal antl-ldlotyplc antibody. Within two weeks about 90 X 
tumour-reduction was established. Although In vitro the tumourcells were 
stimulated by the antl-ldlotype no signs of tumourcell activation were 
observed In vivo. The rapid tumour-reduction suggests that the prolifera-
tion-enhancing property of antl-ld Is not a contra-lndlcatlon for Immunothera-
py. The FcR I I receptors on the patients monocytes could Interact with the 
IgG, monoclonal used. Antibody administration activated the macrophage/mono-
cyte system, reflected In the neopterln profile, resulting In TNFa production 
and simultaneously strong reductions of circulating tumourcells. The latter 
phenomenon suggests a direct involvement for TNFa In tumourcell elimination 
during antl-ld treatment. The partial remission lasted three months, then the 
tumour gradually reappeared. These data show that a straight forward 
therapy with monoclonal antl-ld, In Itself, has a strong potential, but Is not 
sufficient to eradicate the tumour permanently. Further study will be needed 
to Improve the clinical results with this kind of therapy. 
INTRODUCTION 
Tumour therapy with monoclonal antibodies Is hampered at several levels. The 
absence of truly tumour-specific antigens on most tumours Is one of the 
drawbacks; antigenic modulation, mutation of tumourcells and the lack of 
accessibility of all tumourcells may pose other problems. In the case of B-cell 
tumours the Idlotype of these cells can be used as tumour-speclflc antigen 
and monoclonal antl-ld therapy for these types of tumours has been tried out 
and reported on by several authors. After an Initial report of a complete 
remission by Levy et al [12] obtained In a patient with a B-cell lymphoma 
after therapy with monoclonal antl-ldlotyplc antibodies, no other complete 
remissions have been published. Optimism about this kind of therapy has 
been tempered, although In most described cases antl-ld therapy appeared to 
exert a clear anti-tumour effect. Considering the fact that these results were 
obtained mostly In patients, at the end stage of their disease with massive 
tumour burdens, no longer responding to the conventional therapies, the 
absence of a complete remission is not In Itself surprising. Only a minority of 
these patients showed no response et al to this therapy form [2,4,11,12,13]. 
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Here we describe the effects of an antl-ld treatment In a patient with a B-
CLL, who responded Initially extremely well to the administration of (relatively 
small amounts) antl-ldlotyplc antibodies. 
MATERIAL AND METHODS 
Patient 
In 1986, B-cell chronic lymphocytic leukemia (B-CLL) was diagnosed In a 68 
years old woman. On examination, liver and spleen were enlarged and blood 
counts revealed a significant leukocytosis (250x109/l)· Blood cell differentiation 
revealed a large number of IgM.IgD and kappa positive Immature B-lym-
phocytes. In the serum no paraproteins were detectable. The bone marrow 
showed a massive Infiltration with tumourcells. Fourteen months prior to 
therapy with monoclonal antl-ldlotype (MoAb antl-ld), spleen Irradiation (10 
Gy, 1Gy/week) and chemotherapy with chlorambucil (30mg once a week) and 
prednisone (30mg/d) had been given during three months without any effect. 
Thereafter a maintenance therapy was continued with 30mg prednisone and 
5mg chlorambucil a.d. for 1 month followed by a dally dose of 10mg chloram-
bucil until one month before MoAb antl-ld therapy. A moderate reduction of 
the tumour-mass was established. 
At the onset of MoAb antl-ld therapy the number of circulating tumourcells 
was 13.109/l and the concentration of circulating Idlotype was 12 pg/ml serum. 
The patient was Informed and agreed to the MoAb antl-ld treatment, which 
was started with consent of the Ethical Committee of the University Hospital. 
Production of mouse monoclonal antl-ldlotyplc antibodies 
Except for some minor modifications, the production of MoAb antl-ld has been 
similar as described earlier [2,4]. The screening of the monoclonal antibodies 
was performed In mlcrotlterplates (Costar) coated with rabbit anti-human IgM, 
Incubated with IX gelatin (Dlfco), at 37"C, to prevent non-specific binding. 
To these antibody coated plates, tumour Idlotype was bound by incubation 
with a NP-40 (Sigma) tumourcell lysate [16]. 
Simultaneous testing on purified human IgM and IgG (Miles) coated mlcrotlter-
plates made It possible to select Idlotype specific antibody producing hybrldo-
ma's within one screening session. Additional screening to prove specificity 
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and exclude crossreactlvlty with non-tumour tissues and upscallng and 
purification of the mouse IgG, MoAb anti-Id was performed as described 
previously [2,4]. 
MoAb ant I-Id therapy 
The patient was provided with a Hickman catheter, in the vena subclavia to 
facilitate the administration of MoAb anti-Id. The patient was Intensively 
monitored for side effects. During therapy no additional medication except 
al lop uri nol (300 mg/day) was given. The Infusion rate of MoAb antl-ld during 
entire therapy was maintained on 13mg/hr. 
Spleen size was analyzed by echoscopy before, during and after MoAb anti-
Id therapy. Bone marrow samples were examined before and after MoAb antl-
ld therapy. 
Each day, during therapy, blood samples were taken prior to and 15 minutes 
after finishing MoAb antl-ld administration. The following analyses were 
performed: full differential blood count, immunophenotyplng of leukocytes, cell 
cycle analyses; concentrations of electrolytes, complement C3, C4, factor B, 
neopterln, IL-2, soluble IL-2 receptor, TNFa, 02-mlcroglobulln, free Idlotype, 
free MoAb antl-ld, Immunecomplexes and anti-mouse antibodies; liver- and 
kldney-functlons. 
Circulating Idlotype, anti-ldlotype, Idlotype-anti-ldlotype Immune complexes 
and anti-mouse antibodies 
Antl-ld and ldlotype-antl-ld immune complexes (1С) were determined as 
previously described [2]. Circulating Idlotype was determined In ELISA by 
incubating MoAb anti-id coated microtlter plates (Ipg/well) with serial 
dilutions of serum followed by Incubation with peroxidase conjugated rabbit 
anti-human IgG H/L (Miles) and developed with 5-amlnosallcylic acid. The 
absorption was measured at 450 nm with a Tltertek Multlskan. From the titers 
of standard (pre-treatment patient serum with known idiotype concentration) 
and serum samples, the idiotype content was calculated. The titer of anti-
mouse antibodies was determined In ELISA on microtlter plates coated with 
purified mouse monoclonal antibodies (MoAb's) of the subclasses IgG], IgGgy 
IgGjb a n d I 9 G 3 ( e a c h 0.25цд/иеІІ) . 
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Immunofluorescence 
Phenotyplng of mononuclear cells was performed using an Indirect Im­
munofluorescence technique (IF) as described previously [1]. The following 
MoAb's were used to discriminate between B-cells, T-cells and Monocytes and 
to detect the expression of activation antigens: antl-id; B1 (CD20), B4 (CD19) 
Coulter Clone, Hlaleah, FL; anti-μ (kindly provided by Dr. J. Haalman, TNO, 
Rijswijk, The Netherlands); BA-1 (CD24), BA-2 (CD9) Hybrltech, San Diego, CA; 
0KT3 (CD3), OKT4 (CD4) Ortho Diagnostics Systems Inc., Rarltan, N.J.; WT82 
(CD8), WT1 (CD7), WT2 (OKT 10 like), WT14 (CD14), provided by our own 
laboratory; antl-DP, antl-DQ, antl-DR, antl-T9, Ieu7 (Human Natural Killer cell), 
Ieu11 (CDie) Becton and Dickinson Immunocytometry Systems, Mountain 
View,Cal.; UCHM1 (CDU), Mas 018b (antl 02-mlcro) Sera Lab, Sanblo, Uden, The 
Netherlands; In vivo and In vitro, Idlotype modulation was assayed by IF on 
tumourcells after Incubation with MoAb antl-ld. The Idlotype expression 
during therapy was compared with the expression on ρг -therapy tumourcells. 
Determination of TNFa and neopterln 
Commercially available RIA kits were used to determine serum concentrations 
of TNFa (IRE-Medgenlx, Brussel, Belgium) and neopterln (Fa. Henning Berlin 
GmbH, Germany). 
Proliferation assays 
The effect of MoAb antl-ld on tumourcell proliferation In vitro was determined 
as earlier described [1,4]. 
The patients FcR I I was typed in respect whether this receptor could Interact 
with murine IgG,. This was determined by a, FcR I I dependent T-cell 
proliferation assay as earlier described [1,4]. 
RESULTS 
MoAb antl-ld therapy 
The patient showed no immediate hypersensitivity to mouse Ig's as tested by 
subcutaneous Injection of 100 \ig mouse Ig. At the onset of therapy the serum 
contained 12 цд/ті Idlotype and ± 13 χ 1θ'/Ι tumourcells. The Infusion-rate 
of MoAb antl-ld was gradually Increased up to 13 mg/hour without adverse 
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Figure 1. Antl-ldlotype Induced tumour reduction: 
14 21 28 
DRV CF TttRflPY 
a) MoAb antl-ld administration (mg/day) 
b) serum Idlotype (mg/l) 
c) circulating tumourceils (10/1) 
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detectable again. Immunecomplexes were only detectable just after MoAb antl-
ld administration, next morning they were cleared. Dally antl-ld administration 
(Figure la) could clear serum Id (Figure 1b). After day 10 of therapy free 
MoAb antl-ld was detectable In small amounts (2.2 цд/ті) at the end of each 
MoAb antl-ld administration, which had disappeared with the start of the next 
infusion, while serum Idlotype and tumourcelle reappeared Into the circulation 
again (Figure 1c). Further treatment with MoAb antl-ld resulted In a further 
decrease In the amount of reappearing tumourcells. On day 12 the original 
spleen-size of 17 cm had decreased to 11 cm. On day 18, the patient was 
discharged from the hospital. From then on MoAb antl-ld (26.5 mg, In 2 i hour 
Infusions) was given once a week for three weeks. Minor side effects (fever, 
chills, nausea, vomltting, diarrhoea) were observed at the end of the MoAb 
antl-ld administration on days 1, 8, 15, 30, 37 and 44. They disappeared after 
1-1i hour without medication. During the therapy no anti-mouse response 
developed. A total of 773.2 mg MoAb antl-ld had been administered, which 
resulted In about 90% reduction of circulating tumourcells and Idlotype and 
a strong reduction of spleen size. 
Table 1: Differential blood count 
Cell 
Leukocytes a) 
Neutrophils a) 
Eosinophils a) 
Basophils a) 
Monocytes a) 
Lymphocytes a) 
Erythrocytes b) 
Thrombocytes a) 
Hematocrit 1/1 
Hb mmol/l 
day 1 B* 
21.2 
2.4 
0.3 
0.1 
0.53 
17.84 
3.40 
130 
0.35 
6.9 
day 1 A* 
β.4 
5.0 
0.2 
0.06 
0.17 
1.03 
3.48 
33 
0.36 
7.2 
day 51 
6.85 
4.70 
0.06 
0.08 
0.52 
1.48 
3.61 
192 
0.33 
7.0 
a) χ 1071, b) χ lO'VI, *) B/A: Before/After MoAb antl-ld administration. 
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Cell fluctuations Induced by MoAb antl-ld 
Each MoAb antl-ld administration resulted In a strong reduction of the 
tumourcells. However MoAb antl-ld also Induced quantitative variations of 
other blood cells. After each Infusion a granulocytosis and a decrease In the 
number of thrombocytes and monocytes occurred. The red blood cells 
remained stable. An example of these variations Is given In Table 1. 
The leukocyte compartment was analyzed for different lymphocyte subsets by 
marker studies. The results are given In Table 2. 
Table 2: Immunephenotyplng 
Membrane 
markers 
B-cells: 1d+ 
B1+ 
T-ceTIs: CD7+ 
CD3+ 
CD4+ 
СОв+ 
Monocytes:UCHM1+ 
DR+ 
Τ 9+ 
WT2+ 
day 1 B* 
% 
72.8 
72.2 
13.9 
8.6 
7.5 
10.5 
10.7 
82.2 
19.1 
13.4 
day 1 A* 
X 
11.7 
7.6 
21.7 
7.2 
3.8 
16.8 
10.3 
15.8 
21.6 
25.7 
day 51 
X 
47.1 
41.8 
21.6 
9.5 
8.1 
24.9 
30.9 
55.7 
10.0 
33.3 
*) B/A: Before/After MoAb antl-ld administration. 
5 χ 10 mononuclear cells were Incubated with Indicated marker specific 
MoAb's on Ice, washed, developed by FITC labelled goat anti-mouse sub­
class specific antibodies and analyzed by flowcytometry. 
One week after the therapy was stopped (day 51 ), the reduction In the 
number of circulating tumourcells was 95X. The T/B ratio had changed from 
0.19 to 0.46 and the Monocyte/B-cell ratio from 0.15 to 0.66. 
42 
Idlotype modulation 
In vitro, Incubation of 10e tumourcells with 10 цд MoAb antl-ld caused a 
moderate Idlotype modulation. After 2 hrs of culture In the presence of MoAb 
antl-ld, tumourcells expressed 71.1 % of the Initial Idlotype expression. 
Table 3: Modulation of Idlotype expression In vitro and In vivo. 
A) In vitro B) In vivo 
day of 
therapy 
1 
10 
18 
30 
44 
64 
X of pre-therapy 
1d expression 
100 
71.4 
25.1 
48.9 
75.2 
96.0 
time 1n 
minutes 
0 
10 
20 
30 
60 
120 
X of Initial 
Id expression 
100 
93.5 
92.0 
88.2 
80.5 
71.1 
A) 106 tumourcells, obtained before Immunotherapy, were Incubated with 
10 pg/ml MoAb antl-ld during Indicated time at 37*C, after washing 
Indirect IF was used to determine Idlotype expression. 
B) Idlotype expression was determined by Indirect IF on mononuclear cells 
Isolated from blood prior to MoAb antl-ld administration on Indicated days. 
During therapy Idlotype modulation was always observed but was variable, the 
strongest modulation was observed on day 18, at which time the tumourcells 
showed only 25.1 X of their Initial Idlotype expression (Table 3). 
When the MoAb antl-ld therapy was stopped the Idlotype expression on 
circulating tumourcells returned to the Initial expression after 14 days. 
Signs of Immunological activation 
The observed tumour-reduction Indicates an activation of Immunological 
effector mechanisms. Because the nature of the effector mechanisms Involved 
In antibody mediated tumour elimination Is still far from clear, we analyzed 
several parameters which could be a reflection of their activation. 
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Involvement of complement 
When Mo Ab antl-ld was administered, some complement consumption occurred 
as measured by the decrease In concentration of C3, C4 and factor B. This 
consumption Is most likely due to complement binding to the IgM-ldlotype 
complexed with the IgG, Mo Ab antl-ld. Although dally fluctuations occurred, 
the overall concentration of C3, C4 and factor В gradually Increased during 
therapy (Figure 2). This suggests that complement consumption was low or 
that the synthesis could compensate and that complement Is most likely not 
Important In tumour-reduction. 
Figure 2. Complement profile during MoAb antl-ld therapy. 
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( · — · ) : serum C3, (•—•): serum C4, (A—A): serum factor В 
Involvement of monocytes 
Murine IgG, predominantly Interacts with FcR I I which Is polymorphic on 
human monocytes. This polymorphism results In afunctional Inability of about 
30* of the population to react with murine IgG,. Therefore the patients FcR 
I I was typed for the ability to Interact with murine IgG,. The monocytes of 
the patient did express functional FcR for mouse IgG, as determined by FcR 
dependent T-cell mltogenesls (Table 4). Thus monocytes and/or tissue 
44 
1 ί ι 1 ι 1 
7 14 21 28 35 42 49 
DAT OF THERAPY 
macrophages could be able to Interact with MoAb antl-ld opsonized tumour-
cells and IC's. Monocyte counts decreased during each MoAb antl-ld 
administration, but recovered overnight, Indicating a possible Involvement 
of the monocyte/macrophage system. 
Table 4. Determination of a functional FcR I I on adherent cells. 
House Ig subclass of added 
MoAb ant1-CD3 
IgGI (0.5 ug/ml) 
IgG2a (0.5 ug/ml) 
LR T-cells 
cpm ± sd 
755 132 
1173 240 
37764 594 
LR T-cells with 
adherent cells* 
cpm ± sd 
921 118 
27251 2355 
41247 1608 
* ) Allogeneic purified T-cells of a low responder Individual (LR) were co-
cultured with patient's adherent cells (monocytes) with or without MoAb 
antl-CD3. Triplicate cultures were Incubated at 37*C, for 4β hours, 
followed by 24 hours of Incubation with 3H-thymldlne (Amersham, UK). 
Then the cultures were harvested and radioactivity was counted. 
Neopterin profiles 
Macrophages can produce neopterin upon activation, and therefore neopterin 
levels In serum and In urine were determined. The results showed strong 
fluctuations during MoAb antl-ld administration (Figure. 3). 
In general neopterin levels decreased during dally MoAb antl-ld administra­
tions and Increased overnight. After MoAb antl-ld therapy had stopped, 
neopterin levels decreased to nearly normal (10 nmol/l serum). Although the 
neopterlne levels fluctuated strongly, the neopterin production, at the onset 
of therapy, Indicates macrophage activation which gradually decreases during 
therapy and can be Induced again after the Interruption of therapy for one 
week. 
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Figure 3. Neopterln profile during MoAb antl-ld therapy. 
0 7 14 21 28 35 
DAY OF THERAPY 
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( · ) : sample obtained prior to MoAb antl-ld administration. 
(O): sample obtained 15 minutes after MoAb antl-ld administration. 
Table 5. Antl-ldlotype Induced tumourcell proliferation In vitro. 
MoAb ant1-1d 
added pg/ml 
-
0.01 
0.1 
1.0 
10.0 
100.0 
3H-thym1d1ne Incorpo 
- 10X BCGF 
cpm ± sd 
217 46 
312 101 
301 77 
2149 507 
2085 146 
2225 127 
•atlon by tumourcells* 
+ 10X BCGF 
cpm ± sd 
7705 1322 
4944 378 
8374 334 
21819 955 
19447 346 
17535 790 
*) Triplicate cultures of 2 χ IO5 tumourcells were Incubated with Indicated 
concentrations of antibodies, for 24 hours at 37' С 0.5 цСІ 3H-thymldlne 
was added and 24 hours later Incorporated radioactivity was counted. 
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TNFa production 
During therapy TNFa was measured in the serum. MoAb anti-id administration 
Induced TNFa production as is demonstrated most clearly by the Intermittent 
administration on days 30, 37 and 44 (Figure. 4). Whereas during therapy 
breaks TNFa did not change (days 6, 7, 13, 14, 20-30). 
Tumour cell activation 
In vitro Incubation of tumourceils with MoAb antl-id Induced a strong dose 
dependent proliferation which was enhanced by addition of BCGF 10* (Table 
5). During therapy the cells In S-phase were determined. Evidence for In vivo 
Induction of tumourcell proliferation was not found in the circulating cell 
pool. Cell cycle analysis showed less than 1 * of circulating mononuclear cells 
In S-phase, which did not change during nor after MoAb antl-ld administra­
tion. 
Figure 4. TNFa profile during MoAb antl-ld therapy. 
0.8 
0.0 
TNF-alpha p r o f i l e 
9 9 9 
- ι 1 1 1 1 ι 
7 14 21 28 35 42 49 
DAY OF THERAPY 
( t ) : sample obtained prior to MoAb antl-ld administration. 
(O): sample obtained 15 minutes after MoAb antl-ld administration. 
47 
DISCUSSION 
Immunecomplexes and MoAb antl-ld opsonized tu mou reel Is appeared after 
МоАЬ antl-ld administration. Both were eliminated efficiently, resulting In 
about 90X tumour-reduction within 2 weeks. 
Clearance of serum Id coincided with decreases In platelet counts most clearly 
demonstrated on days 1, Θ, 15, 30, 37 and 44 of MoAb antl-ld treatment. We 
have described this phenomenon previously [2,4]. This thrombocytopenia 
might be mediated by FcR 11, which Is present on platelets [9,14]. In line with 
this FcR I I mediated thrombocytopenia are the observations that thrombo­
cytopenia appeared mainly during Immunotherapy with IgG, MoAb antl-ld and 
never with IgG2a or IgGj which Interact with the FcR I which Is not present 
on platelets. Because platelet counts are often decreased In B-CLL patients 
one should be careful with the Infusion-rate of IgG, MoAb's In patients with 
high responder FcR I I , If circulating antigen Is present. 
In our opinion the cells of the monocyte/macrophage system are primarily 
responsible for the tumour-reduction. Monocytes/macrophages could be 
activated by direct Interaction with MoAb antl-ld opsonized tumourcells 
and/or IC's via FcR I I , leading to phagocytosis and production of factors like 
complement components (C3, C4, Factor B), TNFa and neopterln [6,6]. The 
Increase of factor production was demonstrated during MoAb antl-ld therapy. 
Additionally TNFa may have killed tumourcells directly, or may have activated 
granulocyte anti-tumour activity [15]. TNFa may have lead to Increased 
expression of adhesion molecules on endothelial cells for granulocytes and 
lymphocytes, which might explain the rapid clearance of granulocytes and 
lymphocytes from the circulation. Neopterln level was already Increased In our 
patient, compared to normal values, which Is a common feature In patients 
with leukemia [15]. MoAb antl-ld administration did not correlate directly with 
the neopterln profile, but the latter Increased during and after MoAb antl-
ld therapy. A certain lag time for the neopterln release by. In vitro, activated 
monocytes has been described [7] and that may be the explanation for the 
absence of a direct correlation with the MoAb antl-ld administration. The dally 
MoAb antl-ld administrations, resulting In the +90X tumour-reduction, might 
have caused the exhaustion of the phagocytic system, which Is reflected In 
the blood monocyte recoveries, the decrease of maximum neopterln values 
towards the end of the third week of therapy and the tumourcell Idlotype 
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modulation. The weekly administrations of antibodies might not have had this 
effect. When Mo Ab antl-ld was administered at day 30, 37 and 44, the 
neopterln level strongly Increased. If these neopterln data reflect monocy-
te/macrophage anti-tumour directed activity, they suggest that MoAb anti-
id should better not be administered dally, and neopterln levels might be a 
guide for the adjustment of antibody administration In Immunotherapy. We 
have not been able to investigate whether effector-cells of the T-cell lineage 
were Involved In tumourcell elimination. The fact that IL-2 could not be 
detected In serum during tumourcell elimination (data not shown) does not 
necessarily mean that T-cell derived-effector cells were not Involved. Most 
likely T-cells have been Involved, because the release of neopterln Is IFNy 
dependent [7] and IFNy Is a product of activated T-cells. The absence of IL -
2 might be due to consumption by activated CD8+ CTL's and/or NK cells. I t Is 
very likely that the latter were Involved by Interaction with Immunecomple-
xes or opsonized tumourcells, resulting In the production of lymphoklnes like 
IFNy and TNFa [3]. 
In contrast with tumourcells of most other patients treated with MoAb antl-
ld [2,4,10] the tumourcells of this patient were strongly enhanced In their 
proliferation as measured by, In vitro, 3H-thymldlne Incorporation studies. In 
vivo, however, no enhancement of tumourcell proliferation could be detected 
neither by Increased 3H-thymldlne Incorporation, nor by cell cycle analyses 
of circulating mononuclear cells. Tumourcells were eliminated fast and 
efficiently. These findings show that the antl-prollferatlve effect of MoAb 
antl-ld antibodies is not necessarily Involved In the therapeutical outcome as 
was suggested by Lowder et all [10] and our own previous studies [1,2,4] and 
that In vitro stimulation of tumourcells by MoAb antl-ld Is not a contra-
indication for therapy. 
Although the remission obtained was not a long-lasting one, these data show 
that monoclonal antl-ldlotypic antibodies can have strong in vivo anti-tumour 
effects, which might be Improved further by combination with Immuneresponse 
modifiers or conventional therapies. 
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SUMMARY 
Two patients (DEF, BOR) with B-cell chronic lymphocytic leukemia (B-CLL) 
were treated with monoclonal antl-idlotyplc antibodies (MoAb antl-ld). After 
Initial tumour reduction relapse occurred of tumourcells with altered 
functional and phenotyplc properties. In both cases the relapsed tumourcells 
still expressed the same Idiotype but different Ig isotypes. B-CLL cells of 
patient DEF had changed from ц,у,а,6 to weakly positive μ,δ. B-CLL cells of 
patient BOR showed an Isotype change from μ,δ to μ. Besides, the antigens 
reactive with monoclonal antibody BoM22 were expressed In high amounts on 
the relapsed tumourcells of patient BOR. These antigens could also be Induced 
on pre-therapy tumourcells by Incubation with B-cell growth factor. MoAb 
BoM22 Is reactive with the HLA-class I I associated Invariant chain II (g34) and 
precipitates HLA-DR and two additional structures with molecular weights of 
26 kD (p26) and 32 kD (p32). In vitro, the proliferation as measured by ^H-
thymldlne uptake, and the In vitro Idiotype secretion was changed after 
therapy. Tumourcells of patient DEF showed a ten fold Increase In 3H-
thymldlne uptake and a decreased Idiotype secretion in vitro, whereas the 
tumourcells of patient BOR showed no Increase In the proliferative activity, 
but a ten fold Increase of Idiotype secretion. In vivo serum Idiotype level of 
patient DEF had not changed but at relapse the tumour reg row th rate was 
Impressive. In patient BOR the tumour-mass returned to pretreatment levels 
with a twenty-five fold increase In circulating Idiotype. These data Indicate 
that after antl-ld therapy the tumour characteristics In both patients had 
changed. In patient DEF an Immuno-selectlon might have taken place favoring 
the survival and relapse of a less mature, more aggressive tumourcell 
population with a lower Idiotype expression. In patient BOR the antl-ld 
therapy might have triggered the tumour B-cells to differentiate Into a more 
mature form. 
INTRODUCTION 
It has been demonstrated that Immunotherapy with monoclonal antl-idlotyplc 
antibodies has a therapeutic potential [2,7,12,15,17,20], although the final 
outcome of this kind of therapy was generally disappointing except for one 
complete remission reported by Miller et al [17]. Some of these therapy 
failures have been due to alterations of tumourcell characteristics resulting 
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In Idlotype variants [14,19]. Glardlna et al [11] described the simultaneous 
existence of two distinct malignant B-cell clones In one patient, Indicating that 
this might be a cause for therapy failure as well. We have reported on the 
development of non-responsiveness In one of our patients treated with MoAb 
antl-ld ascribing the therapy failure to the exhaustion of the effector system 
[2]. In this report we show that antl-ld treatment may Induce changes In 
tumour-characteristics either by Immunoselection, or by the triggering of 
differentiation. 
MATERIAL AND METHODS 
Cells 
B-CLL (B-cell chronic leukemia) cells obtained from two patients, patients 
DEF and BOR, were Isolated by Flcoll-Hypaque density gradients of heparlnlz-
ed blood, obtained before and after antl-ld therapy and stored until use In 
liquid nitrogen. 
Antibodies 
Monoclonal antl-ldlotyplc antibodies (РАЗ and BorMS), and MoAb BoM22 were 
raised and purified as described previously [2,7]. 
Gel electrophoretlc analysis 
The methods used for the preparation of ^-methionine radiolabeled cell 
extracts, Immunopreclpltatlon with MoAb's and 2D gel electrophoresis of 
Immunopreclpltates were performed as described by Bontrop et al [5,6]. 
Immunophenotyplng 
Immunophenotyplng was performed by Immunofluorescence as described 
previously [3], 
In vitro tumourcell Idotype secretion. 
Pre- and post-therapy tumourcells, 5 χ 10в/тІ In culture medium (RPMI 1640 
DM supplemented with 7.5X v/v heat Inactivated fetal calf serum (PCS), 5X 
w/v gentamycln, 50 μΜ P-mercaptoethanol, 2 mM L-glutamlne and 1 mM 
pyruvate) were cultured for 6 days. The culture supernatant of Mixed 
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Lymphocyte Cultures (MLC sup) was used as a source of differentiation 
factors. The Idlotype concentration In the culture supernatant (CS) was 
determined In ELISA by Incubating antl-ld coated mlcrotlter plates (pg/well) 
with CS followed by Incubation with peroxidase conjugated goat anti-human 
Ig H/L (Nordic, Immunologic, Lab,Tilburg, The Netherlands) and developed 
with 5-Amlnosallcyllc acid. The absorption was measured at 450 nm with a 
Tltertek Multlskan. The OD450 values Indicate the relative Idlotype production 
in vitro culture. 
In vitro tumourcell proliferation 
The proliferative activity of the tumourcells was determined byVl-Thymldlne 
Incorporation as described previously [3]. 
RESULTS 
Immunotherapy 
The Immunotherapy with MoAb antl-ld for both (B-CLL) patients have been 
described In detail elsewhere [1,2,7]. Both patients responded very well 
Initially, resulting In significant but transient tumour reductions (patient DEF 
+ 50« and patient BOR + 90% tumour reduction). 
Patient DEF was treated four times during one year with MoAb antl-ld 
(cumulative dose 24.5 gram), the last two therapy sessions without measurable 
effect. 
Patient BOR was treated 3 weeks dally and three weeks once a week with 
antl-ld (cumulative dose 770 mg). At relapse low doses of rIFNa and rIFNy 
(3x / week subcutaneous!y for 2 weeks: 5 χ 105 units rIFNa and 0.25 mg rIFNy 
Boehrlnger) were administered to the patient In an experimental setting, for 
Immune potentiating purpose. Because of severe side effects the rIFNa/y 
administration had to be stopped after two weeks. The effects of Immunother­
apy on the course of disease In patient BOR Is reflected In Figure 1. Two 
months after the last antl-ld administration (day 100) the tumour gradually 
reappeared, the Idlotype concentration In serum however had Increased 
considerably and reached concentrations much higher than before treatment 
was given and was not related to the tumour mass. At the time of diagnosis 
when the circulating lymphocyte counts were 250 χ 1θ'/Ι and the spleen 
measured 17cm on echography, the Idlotype concentration was 25мд/тІ, at 
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Figure 1. Immunotherapy and tumour relapse (patient BOR). 
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During Immunotherapy a cumulative dose of 770 mg of MoAb antl-ld was 
administered, additionally rIFNa/y was administered: 3x per week sub-
cutaneously for 2 weeks, 5x105 units rIFNa and o.25 mg rIFNy. 
day 100 the Id concentration measured 46.2 ug/ml while the spleen size was 
normal and the lymphocyte count 5.35 χ 109/l of which 80X ld+ cells. The serum 
Id concentration further Increased after rIFNa/y administration up to 270 
цд/ті, together with the tumour load. The patient was treated with chloram­
bucil and finally died from a lunglnfectlon 3 months later. 
Phenotypes, proliferative responses and Idlotype secretion of B-CLL cell 
specimens, obtained before, during and after Immunotherapy, from patients 
DEF and BOR (Table I and I I ) were analyzed, to Investigate whether the 
tumour had changed. 
Phenotype 
About 80 to 90 * of each mononuclear cell suspension, before Immunotherapy 
and after relapse, was reactive with Its own MoAb antl-ld, Indicating that the 
same Idiotypic clone was still present. In both patients the Isotype expres 
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Therapy 
Ant ι-id 
^ 
Therapy 
IFN 
alpha 
gamma 
Table I. Phenotyplc and functional changes of B-CLL cells from patient DEF. 
A) B-CLL phenotype. 
Marker 
1d Isotype * 
1d expression 
HLA-DP 
HLA-DQ 
HLA-DR 
BOM22 
Ρre-therapy 
Ц,5,у,а,К 
++ 
+++ 
++ 
++ 
± 
Post-therapy 
μ,δ,Κ 
± 
+++ 
++ 
++ 
± 
*) All Ig* cells are Id* 
Cryopreserved tumourcells were thawed, washed and Incubated at 4'C with 
Indicated marker specific MoAb's, washed, developed by FITC labelled goat 
anti-mouse subclass specific antibodies and analyzed for fluorescence by 
microscopy. Staining Intensity Is Indicated by low (±) to high («4+). 
B) Proliferative response. 
MoAb ant1-1d 
μ9/ιη1 
10* 
- + 10X BCQF 
10* + 10X BCGF 
Pre-therapy 
cpm ± sd 
416 111 
295 28 
1023 258 
617 82 
Post-therapy 
cpm ± sd 
1852 172 
513 47 
12315 1262 
622 35 
*) MoAb ant1-1d concentration with maximal effect. 
Triplicate cultures of 2 χ 105 tumourcells were Incubated with Indicated 
concentrations of MoAb antl-ld, for 24 hours at 37"C. 0.5 μΟΙ 3H-thymldlne 
was added and 24 hours later Incorporated radioactivity was counted. 
C) Idiotype secretion 1n vitro. 
Culture 
Medium 
Pre-therapy 
OD450 ± sd 
1.080 0.120 
Post-therapy 
OD450 ± sd 
0.280 0.060 
Tumourcells 5 χ lOyml were Incubated, In triplo, at 37"C for б days, 
supernatant was analyzed for Idiotype production In ELISA and expressed 
In OD450. 
5Θ 
Table I I . Phenotyplc and functional changes of B-CLL cells from patient BOR. 
A) B-CLL phenotype. 
Marker 
1d Isotype * 
1d expression 
HLA-DP 
HLA-DQ 
HLA-DR 
BOM22 
Pre-therapy 
U,6,K 
++++ 
+++ 
± 
+++ 
± 
Post ant1-1d 
μ,Κ 
++++ 
+++ 
± 
+++ 
++ 
Post rIFNQ/y 
μ,Κ 
++++ 
+++ 
± 
+++ 
++++ 
* ) All Ig* cells are 1d+ 
Cryopreserved tumourcells were thawed, washed and Incubated at 4*C with 
Indicated marker specific MoAb's, washed, developed by FITC labelled goat 
anti-mouse subclass specific antibodies and analyzed for fluorescence by 
microscopy. Staining Intensity Is Indicated by low (±) to high (++++). 
B) Proliferative response. 
MoAb ant1-1d 
цд/пП 
_ 
1.0* 
+ 1 0 % BCGF 
1.0* + 10X BCGF 
Pre-
cpm 
191 
2178 
2296 
20419 
therapy 
± sd 
40 
246 
906 
4031 
Post 
cpm 
349 
1765 
5019 
26743 
rIFNa/y 
± sd 
88 
252 
713 
36743 
*) MoAb ant1-1d concentration with maximal effect. 
Triplicate cultures of 2 χ 105 tumourcells were Incubated with Indicated 
concentrations of MoAb antl-ld, for 24 hours at 37' С 0.5 μΟΙ 3H-thymldlne 
was added and 24 hours later Incorporated radioactivity was counted. 
C) Idlotype secretion 1n vitro. 
Culture 
Medium 
Medium + MLCsup 
Pre-therapy 
OD450 ± sd 
0 
0.279 0.056 
Post ant1-1d 
OD450 ± sd 
0.128 0.028 
0.478 0.008 
Post rIFNa/y 
OD450 ± sd 
0.888 0.141 
0.966 0.163 
Tumourcells 5 χ 10vml were Incubated, In triplo, at 37"C for 6 days, either 
with or without 10* mixed lymphocyte culture supernatant (MLCsup). The 
supernatant was analyzed for Idlotype production In ELISA and expressed 
In OD450. 
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Sion and on the cells of patient BOR, the reactivity with MoAb BoM22 had 
changed (Table I and I I A). The Idlotype expression of B-CLL cells from 
patient DEF had changed from μ,δ,α,χ to weakly μ,δ. The Idlotype expression 
of B-CLL cells from patient BOR had changed from μ,δ to predominantly μ. 
The reactivity with MoAb BoM22 was strongly Increased, with respect to the 
percentage of reactive cells as well as the expression per cell. An Increase of 
BoM22 reactivity could also be established by a three day Incubation of ρ re-
therapy BOR cells with 10* BCGF In vitro (data not shown). The expression of 
HLA-DP, -DQ and DR as well as of the idlotype remained unchanged. 
Immunopreclpltatlons and gel electrophoretlc analysis 
Immunopreclpltatlons and gel electrophoretlc analysis of 35S-methlonlne 
radiolabeled cell extracts (solublllzed surface- and Intracellular HLA-DR 
molecules) with MoAb BoM22 showed a reactivity with HLA-DR, the Invariant 
chain II (g34) and two additional structures with molecular weights of 26 kD 
(p26) and 32 kD (p32) (Figure 2). BoM22 Is also reactive with HLA-DR positive 
cells In frozen, acetone fixed tissue sections (surface- and Intracellular HLA-
DR) by Immunoperoxldase staining. In contrast, BoM22 appeared to be weakly 
reactive with viable normal- and malignant HLA-DR+ cells as detected by 
Immuno-fluorescence In flowcytometry, with few exceptions. The reactivity 
with HLA-DR, in Immunopreclpltatlons and In fixed tissue sections, must be 
ascribed to the Intracellular Invariant chain (II) associated HLA-DR. When cell 
extracts were precleared for class I I molecules with MoAb TÜ39 (directed 
against the backbone structure of class I I molecules) by repetitive Im-
munopreclpltatlons, MoAb BoM22 precipitated the II chain and the p26 
molecule. 
Therefore the change In reactivity with MoAb BoM22, as determined In 
Immunofluorescence, must be due to the change In expression of II and/or 
the ρ26 molecule. 
Proliferative responses In vitro 
The basic proliferative activity and the response of B-CLL cells from patient 
BOR to BCGF and/or antl-ld (stimulation), In vitro, did not change (Table IIB). 
The response of B-CLL cells from patient DEF to antl-ld did not change 
either, antl-ld still Inhibited the proliferative response. But the basic 
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Figure 2. Reactivity of MoAb BoM22 In Immunopreclpltatlon. 
LUY=HLA-DRw8-DQw3 (BOM22) 
p 3 2 ^ 
LUY(B8.11.2) -A 
D R a _ 
LUY(SPV-L3) -A 
DQa__ 
DR/j/ 
D R ^ 
-4» 
D Q / 4 
g 34 
D 2 6 
1 
LUY(B8.112 A 
+BOM22) 
#
g34 
p32 « · . P 2 6 
DR/3 / ^ 
2D-gel analysis of MLA class I I molecules Isolated from a cell extract of a 
radiolabeled EBV cell line LUY (HLA-DRw8, -DQw3, -0Pw1, w4). The following 
preparations have been analyzed: MoAb BoM22 Isolation (HLA-DR + ?), MoAb 
B8.11.2 Isolation (HLA-DR), MoAb SPV-L3 Isolation (HLA-DQ) and a mixture of 
MoAb BoM22 and MoAb B8.11.2 Isolates. Electrophoretlc analyses were 
performed under Identical conditions, except for the mixture, which was run 
at another time and with different HLA-DR and BoM22 samples. The positions, 
where the various class Π α, β chains, actln (A) and the additional chains 
detected by MoAb BoM22 did focus, have been Indicated (p26, p32, g34= I I , the 
Invariant chain). 
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proliferative activity and the response to BCGF had changed: The BCGF 
Induced proliferation of the post-therapy B-CLL cells was 12 times more 
active than the BCGF stimulated pre-therapy B-CLL cells and 30 times more 
active than unstimulated pre-therapy B-CLL cells (Table IIA). 
Idlotype secretion In vitro 
In vitro the production of Idlotype by post-lmmunotherapy B-CLL cells from 
patient DEF appeared to be reduced (Table 1С), whereas the Idlotype 
production by post-lmmunotherapy B-CLL cells from patient BOR had 
Increased (Table HC). MLC supernatant could enhance Idlotype secretion In 
pre-therapy B-CLL cells from patient BOR but not In post-therapy B-CLL 
cells. The values of Idlotype secretion obtained on day 100 are the Inter­
mediates of the pre- and post-therapy values. 
DISCUSSION 
Previously we described the treatment with MoAb antl-ld for two patients. 
Strong tumour reductions were obtained [1,2,7]. Both tumours relapsed and 
showed changes In phenotyplc and functional characteristics. In both patients 
these changes were not due to the appearance of an Id' clone, the existence 
of a polyclonal malignancy [11] or to Id mutations [14,19]. The relapsed 
tumours still reacted with their corresponding MoAb antl-ld. For patient DEF, 
we ascribed the presence of ц,б,а,у Idlotypes to the coexistence of tumourcells 
with different Isotype constitution and not to a simultaneous expression of all 
Isotypes on the same cell [2]. The change In Idlotype constitution from μ,δ,α,χ 
to μ,δ with a low expression, together with a higher proliferative activity, an 
Increased sensitivity for BCGF and a decreased Idlotype production In post-
therapy B-CLL cells, favors the explanation for Immuno-selectlon of a less 
mature ld+ population In patient DEF. The more pronounced antl-prollferatlve 
activity of MoAb antl-ld on the post-therapy B-CLL cells also suggests a less 
mature B-cell phenotype, because Immature B-cells can be Inhibited by antl-
Ig and mature B-cells cannot [16,21]. This supposition fits well In the models 
of B-cell malignancies In relation to B-cell differentiation as described by 
several authors [10,18]. In patient BOR all data Indicate towards a further 
differentiation of the tu mou reel I. The loss of IgD Is seen when mature B-cells 
are activated with antigen and growth factors and ultimately differentiate Into 
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Ig secreting B-cells [β]. The relapsed population produced more Idlotype, 
which could not be enhanced by differentiation factors obtained from mixed 
lymphocyte cultures (MLCsup). The original population, did not produce 
detectable amounts of Idlotype, but did so In cocui ture with MLCsup, 
Indicating the responsiveness for differentiation factors and the capacity to 
differentiate. The proliferative activity of the B-CLL cells from patient BOR 
was strongly stimulated by MoAb antl-ld and this capacity was not sig­
nificantly altered. The In vitro findings correspond well with the In vivo 
observations: the selection of a less mature more progressive B-CLL cell 
population In patient DEF Is reflected In the Impressive tumour relapse. And 
the differentiation of the B-CLL cells In patient BOR Is reflected In the 
Increase of circulating Idlotype, an observation also reported by Meeker et 
al [15] for a patient with a B-PLL. Bertoll et al [4] described the development 
of large cell lymphoma from a B-CLL carrying the same Idlotype, whereas 
Fermand et al [9] described the coexistence of a B-CLL and a Multiple Myeloma 
which shared Idiotypic determinants. An intriguing phenomenon Is the 
expression of the antigens p26, p32 and II (assuming that II might be 
expressed on the cell-surface) recognized by BoM22. The reactivity of the 
"more mature" population of B-CLL cells In patient BOR was strongly 
Increased. The recognized molecules, a combination or each one of them, might 
be Indicative for a certain differentiation or activation stage. The finding that 
the culture of pre-therapy tumourcells of patient BOR with BCGF could Induce 
the expression of these antigens, strongly suggests a role for these antigens 
In either the differentiation or activation of B-cells. On the other hand the 
expression of these antigens may be an aberration belonging to the tumour. 
We conclude that the antl-ld therapy Induced or accelerated the selection of 
the Immature tumour population In patient DEF by eliminating those cells with 
a higher Idlotype expression and the Isotype constitution other than μ,δ. The 
B-CLL cells from patient BOR developed Into a more mature stage of differen­
tiation. MoAb antl-ld therapy Is most likely responsible for this differen­
tiation. The antl-ld administration Induced the production of TNFa [1] that 
started the differentiation process [13], which may have been enhanced by 
the administration of rIFNa/y. These, so different findings for only two 
patients, further confirm the Idea, that the understanding of the mechanisms 
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underlying the curative effects of tumour therapy with monoclonal antibodies 
or other biological response modifiers Is still at the beginning. 
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Anti-Ig antibodies can have two opposing effects on B-cell proliferation, resulting cither in 
stimulation or inhibition We have examined the proliferative response of 10 B-cell tumours to 
anli-lg in the presence and absence of B-cell growth factor Three reaction patterns were 
observed In 12 cases a dose-dependent synergism between anti-Ig and B-cell growth factor was 
present in the induction of proliferation, in ten cases anti Igdid noi induce any response, and in 
eight cases anti-Ig suppressed the B-cell growth factor (BCGF)-induccd proliferation Similar 
responses to anti-Ig »ere found in Ihe absence of BCGF When these B-cell tumours were 
typed for expression of Ig isoivpcs HLA class II antigens several В cell markers activation 
markers complement receptors Fc rcceplors cell size and cell evele phase no correlation 
could be found wilh the proliferative response of these lumour В cells to anti-Ig Τ cells or T-cell 
factors were not involved, because T-cell depletion did nol change the lumour B-cell prolifcra-
uve response to incubation with antl-Ig The observed inhibition of proliferation did not 
correlate with the expression of I с receptors indicating the involvement of suppressor mechan 
isms other than the cross-linking of Fc receptors with surface immunoglobulins Tumour В 
cells, for which monoclonal anti-idot>pic antibodies (MoAb anti-id) were available, responded 
to MoAb anil-id in the same wa> as Ihey did to anil Ig In view of the treatment of B-cell 
malignancies with MoAb anti-id, ihe question of whether these responses in vitro correlate with 
in vivo clinical outcome of anti-id therapy is of interest So far our data show that the 
proliferative response of B-cell tumours to anti-Igor MoAb anti-id is heterogeneous and cannot 
be linked to phenotypc, is Τ cell-independenl. and is most likely an intrinsic property of the 
malignant cell 
W A Allcbes, Department of \ephroU)g\ Unnersity Hospital Geert Grooteplein Zuid Η 6525 
GA Nijmegen, The Netherlands 
The incubation of В cells with anti-Ig antibodies 
(anti-Ig) results in a cascade of reactions which 
can ultimately lead to proliferation [5, 6] At 
relatively low concentrations (1-5 μg/ml anti-
Ig), resting В cells enter the G, phase and 
require T-cell factors to proliferate [10] and with 
higher concentrations (±50 μg/ml anti-Ig) they 
start to proliferate directly [5,6] Activation of В 
cells by cross-linking of surface Ig by anti-Ig is 
accompanied by many reactions, changes in 
phosphoinositol metabolism, an increase in 
intracellular free calcium concentration, mem­
brane depolarization, and activation of protein 
kinase С [25] This cascade of reactions leads to 
an increased HLA class II expression [25] and 
also increases expression of the oncogenes c-fos 
and c-myc. 
Tumour cells are often used for studying 
anti-Ig reactivity of В cells Enhancement of 
proliferation by anli-lg and anti-id has been 
described [32] On the other hand, some authors 
have reported an anti-proliferative effect of 
anti-Ig or monoclonal anti-idiotypic antibodies 
(MoAb anti-id) [12, 14] In view of the develop­
ment of in vivo therapy of B-ccll malignancies 
with MoAb anti-id [2, 15, 18, 24] it is important 
to know which signals are given to the tumour 
cells, and whether the response is predictable by 
phenotypic analysis Therefore we analysed 30 
B-cell tumours as regards their in vitro prolifera-
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Uve response to anti-Ig and in some cases to 
MoAb anti-id in relation to their phenotype We 
also investigated whether Τ cells were involved 
in the proliferative response of these B-tell 
tumours to anti-Ig 
MATFRIA1 S AND MLTIIODS 
Patients Twcnly-thrcc palicnls were diagnosed as 
having (.hronic lymphocvlic leukaemia (CLL), six 
patients were suffering from follicular ccntrocy tic non-
Hodgkin s lymphoma and one patient was diagnosed 
as having a Durkit lymphoma 
Cells Cell lines K%2 HL60. and СЕМ were used as 
referent cell lines in the Fc receptor (FcR) assay and 
maintained in culture medium (RPM1 1Ы0 DM sup­
plemented with 7 Я% vol/vol heat inactivated fetal 
calf scrum (FCS) 5% wt/vol gentamycin, SO μΜ 
/3-mercaptoethanol. 2 mM L-glutamme and 1 т м 
pyruvate) Mononuclear eel Is were obtained by Ficoll-
Hypaquc gradient centnfugation using blood in case 
of heallv donors or CLL patients, and dispersed lymph 
nodes in case of lymphomas Cells were cryopreserved 
until use 
Antibodies Anli-lg was purified from hyperim­
mune serum of human Ig-immum/ed rabbils by pre­
cipitation and affimtv chromatography Pepsin 
digestion of anti-Ig and subsequent isolation of F(ab ), 
fragments was performed as described by Capei et al 
[Ч| Aggregated rabbit IgG (A-R-IgG) was obtained 
by incubating purified normal R-!gG (20 mg/ml) for 
15 mm at 63°C A-R-IgG were stored at -20°C in a 
concentration of 1 mg/ml (PBS S% BSA, 0 01% 
NaN), pH 7 4) The preparation of MoAb anti-id has 
been described previously [2] 
Cell Proliferation Crvoprescrved tumour В cells 
were thawed quickly, washed twice, and resuspended 
m culture medium 2x10 s cells were incubated with 
different concentrations of anti-lg or MoAb ami id 
(100 10, 1,0 1 Mg/ml) in the presence or absence of 
10% B-cell growth factor (BCGF, no contamination 
with phylohaemagglutimn (РИА), gamma interferon 
(IFN-y) or intcrleukin 2 (II -2) Cellular Products Ine , 
Buffalo Ν Y USA) Triplicate cultures in 96-wcll 
microtitre plates (Flow Laboratories Uxbridge, Mid­
dlesex, UK) were incubated for 48 h followed by 24 h 
with 0 5 дСі per well ('Hlthymidinc (Radiochemical 
Centre, Amersham Bucks , UK) At 374. 5% CO, 
m air, and l(Kl°o relative humidity Then the cultures 
were harvested and incorporation of radioactivity was 
measured by counting The results are presemed 
either as mean cpin±SD. or as stimulation incides 
(SI) SI=mean cpm of ['Hlthymidme incorporation in 
cultures incubated with anti-Ig divided by the mean 
cpm of [1H]thymidine incorporation in the cultures 
incubated in the absence of anti-Ig 
Depletion of Τ cells from tumour B-cell suspensions 
Contaminating I cells within the tumour В cell sus­
pensions were removed by treatment with anii-T-ccll 
MoAb (WT32. CD3, WTl. CD7, WT82 CD8) and 
baby rabbit serum as complement source The absence 
of l-ccll proliferation (by means of ['Hjlhymidine 
incorporation as described before) induced by PHA. 
concanavahn A (Con A), and MoAb anti-CD3 
(WT32) after treatment was used as evidence for a 
successful T-cell depletion 
Immune phenotypmg Phenotypmg was performed 
with an indirect immunofluorescence technique (IF) 
Briefly, cells were incubated with MoAb antisera or 
A-R-IgG (0 1-100 Mg/ml) for 30 mm on ice, washed 
with IF buffer (phosphate buffered saline (PBS), 1% 
bovine serum albumin (BSA), 0 01% NaN,) and 
developed with fluorescein isothiocyanale (FITC)-
labellcd antisera (sheep anti-mouse Ig-FITC Cappel, 
West Chester, Pa , goat anti-rabbit Ig-FITC, 
Kallestadt, Chaska, Minn , USA) Finally the cells 
were washed and fixed with 2% paraformaldehyde 
10 000 cells/sample were analysed with an Ortho H30 
cytofluorometer Positively stained cells after correc­
tion for the negative control (ι e cells only incubated 
with the FITC-labelled antisera. in general 15%) 
were analysed for their mean fluorescence intensity 
(MFI) on a linear scale Rabbit antisera specific for 
human IgM. IgG, IgA. IgD, IgF kappa-, and lambda-
light chain (Central Laboratory of the Red Cross 
Blood Transfusion Service (CLB), Amsterdam I he 
Netherlands) were used to determine the expression of 
isotype and light chain A R IgG was used to quanti-
tate the Fc receptor (FcR) expression MoAb were 
used to discriminate between В cells, Τ cells, and 
monocytes and to detect the expression of other mark­
ers, which are known to be related ιο В cells or malig­
nant cells or involved with cell activation I hese 
MoAb are OKB(2) (B cell) OKB7 (CD2I), NEIO.Ti 
(СШ4) NLI040 (B cell), OKTl (CD5). OKT3 
(CD3) OKT4 (CD4), WTl (CD7), W П2 (CD3). 
W,T82 (CDS), OKM1 (CDllb) OKM5 (monocyte), 
NEHMT (monocyte), WT14 (CD14), anli-DQ anti-
DR anti DP anti CRI anti CRII (CD21) anti-
CRIII (CDllb), anti-T9 (transfernnc receptor), and 
NEKm (CDU) All the OK MoAb were obtained 
from Ortho Diagnostic Svslems Ine (Ranlan. N J . 
USA) all the NEI MoAb were obtained form New 
England Nuclear (St Albany Boston Mass USA), 
all the WT MoAb were provided by our own labora­
tory. and the remaining MoAb were obtained from 
Becton Dickinson (Immunocytometry Systems, 
Mountain View Calif USA) 
R E S U L T S 
Proliferative responses to anti-Ig or MoAb 
antt-id 
In all cases more than 90% of the isolated cells 
provided to be of B-ccll origin One type of light 
chain was expressed by each B-cell tumour, 
indicating the monoclonal character of the 
malignity Fifty-three per cent of the tumours 
showed kappa light chain expression and 4 7 % 
expressed the lambda light chain The prolifera­
tive response of these tumours to anti-Ig was 
studied Cells from 30 patients were incubated 
with various amounts of anti-Ig. ranging from 1 
to 100 μ§/Γτι1 in the presence or absence of 
B C G F (10%) Table I shows examples of the 
[ 'Hlthymidme uptake of nine tumours incu-
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TABLE I [3H] thymidine incorporation by B-cell tumours 
Tumour 
Bor' 
Bor' 
Vdb' 
Hil' 
Hil-
DeP 
Def* 
Míj1 
Vga' 
Vdl' 
Pie2 
Vst' 
['Hjthymidine ince 
Medium 
256±13 
256±13 
641 ±29 
473 ±48 
473±48 
1974±403 
1852±172 
1847±80 
961±103 
124 + 29 
1206±427 
126±19 
Anti-Ig 
2513±113 
2225±127 
9839±593 
2256+38 
1216+43 
488 ±49 
513+47 
243±118 
382±37 
174 + 62 
1327±36 
nd 
)фога1іоп (mean 
BCGF 
7705 ±1322 
7705±1322 
5762 + 594 
8302±320 
8302±320 
10776±1297 
12315±П62 
5161±564 
6243 ±1102 
1025±88 
12995±2434 
143±23 
cpm±SD) 
BCGF+anti-Ig 
29951+939 
17535 ±790 
31702+1593 
19095 ±830 
31494±851 
2907±42 
2622±35 
438±73 
1316±205 
1333+205 
12696±1300 
215±100 
Triplicate tumour B-cell cultures (2x10s) were incubated for 72 h, in the 
presence or absence of 100 μ&τηΙ anti-Ig/anti-id or 10% BCOF as indicated 
The last 24 h they were pulsed with pH]thymidine 
'Incubations performed with anti-id (100 /tg). nd. not done 'B-CLL, 2B-
NHL. 
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FIG 1 Dose-dependent proliferative response of 30 B-ccll tumours to incubation 
with anti-lg in the presence of 10% BCGF 
bated with or without BCGF and/or anti-lg 
(100 ^g/ml)oranti-id(100 Mg/ml). BCGF alone 
stimulated the |'H]thymidine uptake up to 30 
times the initial actmtv Twenty-six tumours 
were stimulated, four were unaffected. 
Anti-id had the same effects as anti-lg, as 
illustrated by tumours Bor. Hil. and Def (Table 
I) The dose-dependent proliferative responses 
to anti-lg in the presence of 10% BCGF, for all 
30 B-cell tumours, are given in Fig. 1 and indi­
cate three types of reaction patterns Tumour В 
cells with SI values ?2.0 were defined as being 
stimulated, those with SI values €0 6 were 
defined as inhibited, meaning more than 40% 
inhibition, and tumour В cells with SI values 
between 2 0 and 0 6 were defined as being non-
responsive. Standard deviations have been omit­
ted Generally they were less than 20%. Twelve 
tumours were stimulated, eight tumours were 
suppressed, and 10 tumours were non-respon­
sive according to our criteria. Two examples 
illustrating that dose-dependent proliferative 
responses to anti-lg and anti-id are comparable 
are given in Fig 2. 
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FIG 2 Dose-dependent proliferative response of В cell tumours PI (Hil) and PI5 
(Def) to MoAb dnti-id (both of (he murine IgG 1 subclass) or anli-Ig in ihe presence ' 
of 10% BCGF ( · · ) MoAb anti-id PI, (O O) MoAb ami-id P15. 
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FIG. 3 Effectivity of Τ cell-depletion by treatment with MoAb anli-CD3, CD7, and 
CDS and rabbit complement measured by T-cell mitogenesis with PHA, Con A, and 
MoAb anti-CD3 (D) Untreated cells,"(O) cells incubated with RC; (•) T-cell 
depleted cells, HI, healthy individual, Ρ4 (Cor) and P15 (Def), patients with B-cell 
tumour 
T-cell independence of anti-Ig induced 
proliferative responses 
The heterogeneous responses to anti-Ig may 
be caused by contaminating Τ cells. Therefore Τ 
cells were depleted from the tumour cell suspen­
sions by incubation with a cocktail of antibodies 
directed against T-cell antigens (CD3, CD7, and 
CD8) in the presence of rabbit complement. The 
effectivity of this treatment was demonstrated 
by T-cell mitogenesis with PHA, Con A, and 
anti-CD3 before and after treatment (Fig. 3). 
When cells were incubated with anti-Ig after 
T-cdl depletion, normal В cells no longer 
responded to anti-Ig, despite the presence of 
BCFG, whereas the response of the tumour cells 
remained unaltered, as shown in Fig. 4. Table II 
shows that the response to anti-Ig did not 
depend on the presence of BCGF after T-cell 
depletion. 
Proliferative responses and phenotype 
Eleven representative B-cell tumours were 
analysed in more detail, to investigate whether 
the heterogeneous responses of tumour В cells 
to anti-Ig or anti-id were reflected in the expres­
sion of membrane antigens likely to be involved 
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FiG 4 Dose-dependent proliferative response of tumour В cells Cor(P4) Dcf 
(P15) and normal В cells (Ml) to incubation with anli Ig in the presence of 10% 
BCGF before (O O) and after Τ cell depletion ( · — - · ) 
TABLE II В cell proliferation after T-ccIl depletion 
Cells 
Def' 
Dcf (-T) 
Cor' 
Cor (-T) 
PBL 
PBL (-T) 
Medium 
1307±119 
1249±51 
291+29 
341±1П 
507 + 76 
210±68 
Mean cpm±SD 
Anti-Ig 10% BCGF 
651 + 24 
335 ±24 
2211 ±166 
1923±95 
203U±442 
463 ±75 
5843+620 
6392±1590 
556+224 
279±108 
2392±161 
635±128 
Anti Ig + BCCI 
29861290 
14691122 
51131283 
3186198 
72461452 
764196 
Tumour cells Def Cor, and PBL cells were Τ cell-depleted by incubation 
with anti Τ cell MoAb (anti CD3, anti-CD7 and anti-CD8) and baby rabbit 
complement Then the cells were washed and resuspended in the same volume 
as the untreated cells and the proliferative response was measured as described 
in Table I 'B CLL 
TABLE III Suppression of ('Hjthymidme incorpora­
tion in B-cell tumour Def (B CLL) 
Addition of 100 Mg 
antibody 
IgG anti-Ig 
F(ab')2 anti-Ig 
IgGl anti id (Def) 
IgM ami id (Def) 
IgGl anti id (Hil) 
Mean 
Medium 
18521172 
488149 
425133 
513147 
361111 
16711221 
cpm + SD 
10% BCGF 
1231511262 
1400176 
28401182 
622135 
770169 
13122+1532 
1 nplicate cultures of Def B-CLL cells (2 χ 10s) were 
incubated for 72 h and pulsed with ['HJlhymidine for 
the last 24 h Incorporation was measured nd not 
done 
in B-cell regulation We analysed FcR involve­
ment in the inhibition of proliferation Tumour 
cells that had been inhibited by intact anti-Ig 
were incubated with Р(аЬ')т anti-Ig and also with 
two MoAb anti-id of different isotypes, one 
IgGl which could interact with the IgG FcR and 
an IgM which does not interact with this FcR 
An unrelated anti-id was used as a control for the 
MoAb anti-id The results shown in Table III, 
show that the observed inhibition of prolifera­
tion was independent of Fc On the other hand, 
we analysed the presence of FcR for rabbit Ig on 
tumour cells (because the anti-Ig used in this 
study is of rabbit origin) and the results obtained 
with 50 μg/ml A R-IgG are given in Table IV 
The cell lines K562 and HL-60 were used as 
positive controls for the FcR assay and the cell 
line СЕМ as a negative control All tumour cell 
suspensions contained less than 10% non-B cells 
and therefore the expression of FcR above this 
percentage must be ascribed to the tumour В 
cells These results show that the differences in 
proliferative response of tumour В cells to 
anti-Ig are not reflected in the presence or 
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TABLE IV Expression of FcR on different tumour В 
cells* 
TABLE VI Expression of complement receptors type I, 
II, and III on different tumour В cells* 
Cells 
Bor' 
Hey' 
Vdb2 
Vdoi 
Def' 
Míj' 
Vga' 
Deb' 
Hus2 
Dek2 
Dod' 
K562 
HL60 
СЕМ 
Proliferative 
response to 
anti-Ig 
Stimulation 
Stimulation 
Stimulation 
Stimulation 
Inhibition 
Inhibition 
Inhibition 
Inhibition 
Unaffected 
Unaffected 
Unaffected 
50 
(%) 
22 
25 
24 
26 
13 
18 
19 
η 
48 
20 
19 
80 
81 
7 
Mg/ml 
MFI 
604 
105 7 
616 
53 4 
51 1 
126 9 
63 2 
72 9 
75 3 
91 7 
75 9 
50 Я 
37 7 
50 3 
Cells 
Bur' 
Hey' 
Vdb2 
Vdo2 
Def' 
Míj1 
Vga' 
Deb' 
Hus2 
Dek2 
Dod' 
Proliferative 
response to 
anti-Ig 
Stimulation 
Stimulation 
Stimulation 
Stimulation 
Inhibition 
Inhibition 
Inhibition 
Inhibition 
Unaffected 
Unaffected 
Unaffected 
'Differential CR 
CRI 
(%) 
11 
13 
13 
7 
8 
11 
12 
3 
7 
9 
5 
MF1 
45 0 
44 2 
27 3 
56 8 
48 6 
39 6 
25 0 
38 2' 
36 2 
33 3 
410 
expression 
CRII 
(%) 
14 
20 
41 
5 
14 
24 
51 
2 
6 
31 
6 
was 
М П 
40 9 
40 2 
24 3 
45 9 
38 5 
36 1 
22 2 
37 2 
33 5 
24 8 
37 2 
CRIII 
(%) MFI 
10 44 5 
16 38 1 
8 35 8 
6 54 6 
13 47 5 
19 40 6 
7 48 2 
5 36 7 
9 34 3 
9 41 8 
11 36 9 
ι quantitatcd by 
cytofluorometrv The percentage of positive 
correction for the nei 
cells after 
gative control (conjugate incuba-
*FcR expression was qudntitated with the aid of 
50 μ^ ΓηΙ aggregated rabbit IgG and binding was 
scored by cytofluorometry The percentage of positive 
cells after correction for the negative control (conju­
gate incubation alone, ±5%) and the mean flúores 
cence intensity (MPI, on a linear scale) for the 
positively stained cells are given for the individual 
B-ccll tumours 'B-CI I TBNHI 
TABI F V Expression of ULA class II antigens DQ, 
DR and DP on different tumour В cells* 
Cells 
Bor' 
Hey' 
Vdb2 
Vdo2 
Def' 
Míj' 
Vga' 
Deb' 
Hus2 
Dek2 
Dod' 
Proliferative 
response to 
antigen 
Stimulation 
Stimulation 
Stimulation 
Stimulation 
Inhibition 
Inhibition 
Inhibition 
Inhibition 
Unaffected 
Unaffected 
Unaffected 
DP 
(%) 
67 
69 
72 
22 
63 
77 
33 
22 
40 
58 
39 
MFI 
46 4 
63 8 
46 2 
34 5 
58 3 
29 9 
50 8 
25 4 
31 5 
31 9 
25 4 
DQ 
(%) 
16 
52 
68 
14 
60 
61 
14 
18 
19 
58 
37 
MFI 
38 7 
41 7 
45 1 
30 4 
25 4 
24 2 
37 9 
22 2 
27 6 
34 5 
34 5 
[ 
(%) 
66 
79 
77 
48 
79 
90 
29 
43 
47 
77 
51 
Ж 
MFI 
154 9 
104 5 
110 9 
43 2 
1155 
98 6 
95 5 
54 5 
80 5 
109 6 
65 5 
'Differential HLA class [I antigen expression was 
quantitated by cytofluorometry The percentage of 
positive cells after correction for the negative control 
(conjugate incubation alone, ±5%) and the mean 
fluorescence intensity (MFI on a linear scale) for the 
positively stained cells are given for the individual 
B-cell tumours 'B-CLL 2B NIIL 
absence of FcR We also analysed the relation 
between the proliferative response and the dif­
ferential expression of class II molecules on the 
cell surface of the representative B-cell tumours 
The results in Table V show no correlation 
between differential HLA class II expression 
lion alone, ±5%) and the mean fluorescence intensity 
(MFI, on a linear scale) for the positively stained cells 
are given for the individual B-cell tumours 'B CLL 
2B-NHL 
and the observed reaction pattern to incubation 
with anti-Ig For the same selection of В cell 
tumours, we analysed the expression of the com­
plement receptors CR I, CR II and CR ΠΙ The 
results, given in Table VI, showed no correlation 
between the differential CR expression and 
anti-Ig responsiveness 
DISCUSSION 
Our results show that B-cell tumours which 
express surface Ig display different reaction pat­
terns when incubated with either anti-Ig or 
MoAb anti-id In 26 out of 30 cases the addition 
of BCGF alone significantly increased a basic 
['Hlthymidme incorporation, indicating the sus­
ceptibility of these cells to BCGF When anti-Ig 
was also present, a synergistic effect was found 
in 12 cases, an effect which also occurs with 
normal В cells [20] One could argue that these 
responses may be due to the contribution of 
contaminating normal В cells The con­
tamination of non-tumour cells is less than 10%, 
including monocytes and Τ and В cells, and 
assuming that within these 10% of non-tumour 
cells the differentiation is normal, then ± 3 % 
normal В cells could be present The ['HJthy-
midine uptake of 6x 10' normal В cells is below 
detection under the culture conditions used, 
thus indicating that the effect of anti-Ig is not due 
to contaminating normal В cells Besides, we 
73 
Heterogeneous Tumour B-Cell Proliferation 
have shown that anti-id induces identical 
responses compared with anti-Ig and these 
responses must be ascribed to the tumour cells 
In contrast to the findings of Mongim et al [19], 
who found that leukaemic В cells were stimu­
lated by anti-IgM, and were suppressed when 
co-cultured with T-cell supernatant, we found 
that all B-cell tumours stimulated with anti-Ig 
were synergistically stimulated with the com­
bination of anti-Ig and BCGF The findings of 
Mongini et al [19] suggest that tumour В cells 
responsive to T-cell supernatant can be stimu­
lated by anti-Ig and that tumour В cells not 
affected by T-cell supernatant are susceptible to 
inhibitory signals transmitted by anti-Ig Our 
results do not support this suggestion, because 
the heterogeneous responses to anti-Ig were 
independent of BCGF This might be explained 
by the different additives used T-cell superna­
tant, containing IL-2 and IFN-y, versus a BCGF 
preparation without these activities Another 
difference can be found in the B-cell tumours 
used hairy cell leukaemia (HCL) versus chronic 
lymphocytic leukaemia (CLL) and non-
Hodgkin's lymphoma (NHL) In this study the 
responses provoked by MoAb anti-id and poly­
clonal anti-Ig were comparable, most likely 
because these MoAb recognize idiotopes which 
allow inter-membrane Ig cross-linking, which is 
necessary for signal transduction [19], and not 
intra-idiotype cross-linking [8] 
Anti-Ig and BCGF not inducing significant pro­
liferative responses in purified В cells, is in con­
trast to previous findings [20, 21, 32] We used В 
cells punfied by T-cell depletion with MoAb and 
complement a treatment that might have affected 
the normal В cells and their responses to anti-Ig 
and BCGF On the other hand, T-cell depletion 
by treatment with MoAb anti-CD3, anti-CD7, 
and CD8 might be more effective than elmmation 
ofTcellsbyAET-SRBCrosettmg The remaining 
Τ cells in the latter case may provide additional 
growth factors 
In eight cases anti-Ig suppressed the spon­
taneous and the BCGF-enhanced [3H]thymidine 
uptake Suppression by Τ cells or T-cell sup­
pressor factors are most likely not involved m 
this phenomenon, because T-cell depletion did 
not change tumour cell responses to incubation 
with anti-Ig, with or without BCGF Further­
more, it seems unlikely that monocytes/ 
macrophages are responsible for the hetero­
geneous responses of tumour В cells on incuba­
tion with anti-Ig, because with the procedure of 
T-cell depletion, adherent cells were depleted as 
well 
WEHI-231 cells are being suppressed by 
anti-Ig in the G, phase of the cell cycle [27, 28] 
A cell cycle-dependent suppression of tumour 
cell proliferation seems unlikely in our case, 
because cell cycle analysis showed more than 
95% in Go/G, phase and the absence ot IV anti­
gen indicates that these cells must be in Go 
phase, T9 being expressed by В cells in all phases 
except the G,, phase [11] Concomitant cross-
linking of slg and FcR by anti-Ig can be suppres­
sive [1, 23] We found that the anti-Ig-induced 
inhibition of proliferation was Fc-independent 
because the tumour cells tested responded simi­
larly to F(ab')
:
 anti-Ig and to intact anti-Ig, 
indicating that FcR is not involved Further­
more, IgM MoAb anti-id, which could not inter­
act with the IgG FcR, was as effective as IgGl 
anti-id in the inhibition of proliferation These 
data and the findings that FcR expression did not 
correlate with the proliferative reaction patterns 
found, suggest an FcR-independent suppressor 
mechanism Similar findings have been reported 
by Mongmi et al [19] 
It is known that В cells can be inhibited by 
anti-Ig, depending on their stage of maturation 
Neonatal В cells [7, 16, 29], nascent slg* bone 
marrow cells [17, 26], and stimulated memory 
precursor В cells [13], are inhibited by anti-Ig, 
whereas mature В cells are not inhibitable by 
anti-Ig [17, 26] Several authors [4, 9, 22] have 
reported that HLA class II antigens play a role in 
B-cell activation, proliferation, and differentia­
tion, and different roles have been described for 
HLA-DQ and HLA-DR [9] Expression of com­
plement receptors CRI and CRII may reflect a 
state of activation and/or differentiation within 
the B-cell lineage [30, 31], in which В cells are 
susceptible to regulatory signals When we ana­
lysed the cells for cell size, slgM/sIgD ratio, the 
qualitative and quantitative expression of slg 
isotypes, and HLA class II, CR, and FcR, we 
were unable to relate the different anti-Ig 
responses to these phenotypic markers We 
therefore conclude that the proliferative 
response to anti-Ig must be an intrinsic property 
of the tumour В cell and cannot be predicted by 
phenotypic analysis as described here 
The use of MoAb anti-id is a recent 
development in tumour therapy Krolick et al 
[12] reported in vitro and in vivo inhibition of 
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tumour cell proliferation by MoAb anti-id 
Lowder et al [14] reported in vitro a strong anti­
proliferative effect by MoAb anti-id to correlate 
with in vivo tumour reduction We have 
described a strong in vivo tumour reduction by 
MoAb anti-id, which had a strong anti-prolifera-
tive effect on tumour cells in vitro [2] So far, no 
imunotherapy with MoAb anti-id has been 
reported in patients whose tumour cells are 
strongly stimulated to proliferate in vitro bur-
ther studies on the interaction of anti-id and 
tumour cells in vitro and in vivo during immu­
notherapy will have to be carried out before the 
relation between tumour cell proliferation and 
the outcome of anti-id therapy can be evaluated 
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CHAPTER 7 
GENERAL DISCUSSION 
GENERAL DISCUSSION 
Because of possible tumour-speclflclty and supposed absence of severe 
Irreversible side effects, the treatment of malignancies with monoclonal 
antibodies Is an approach which Is worth to be explored. Within the numerous 
different tumours, the B-cell malignancies are unique with respect to the 
expression of truly tumour-speclflc antigens: The Idlotopes. The Idlotype, the 
combination of Idlotopes, Including the antigen binding site. Is the protein 
product of rearranged Ig VL- and V))-chaln germllne-genes [1] of each 
Individual B-cell. Once the rearrangement, has ocurred, the offspring of each 
B-cell, can be considered as a clone with unique clone-specific antigenic sites, 
expressed on the cell surface, the Idlotype. In general B-cell malignancies 
have been proven to be monoclonal, I.e. arisen from a single precursor cell 
[13,23,36]. Therefore the s-Ig+ B-cell tumours express a truly tumour-speclflc 
entity, the. Idlotype. 
I t Is Important, to know, how many patients could be considered for this type 
of therapy, when they are selected not only on the base of a B-cell malignan-
cy but also on a good cell-surface Idlotype expression and the absence of 
paraproteins. Our experience was that of 32 B-cell malignancies, 19 did 
express sufficient Idlotype, 14 of them had no paraprotein and after 
considering the physical and clinical conditions only 7 patients could be 
selected. We were not able to prepare antl-ld for all of them In time, and 
actually we could only treat three patients. From other reports on antl-ld 
treatment [17,27] and our own experience It is clear that a high level of 
circulating Idlotype Is a contra-lndlcatlon for therapy. After preparing the 
anti-id, the level of circulating Idlotype can be determined. If we would also 
have selected those patients with a low Idlotype concentration, then only one 
would have met the criteria as mentioned above. This means that with these 
criteria, in our study only 3* of the patients should have been considered for 
therapy. 
The approach of antl-ld treatment Is very attractive at the level of speclflclt-
y. However, for each patient an Individual monoclonal antibody has to be 
developed, which Is very time consuming. The time schedule of our protocol, 
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Figure 1. PRODUCTION OF MoAb ANTI—ID 
1. Immunization of BALB/c mice 4 weeks 
with tumourcells In CFA 
2. Fusion of mouse myeloma SP2/0 with Inmune spleen cells 
3. Screening of hybrldoma's on ant1-1d production 
and subclonlng: 
ELISA on Idlotype 
ELISA on human Ig 
ELISA on tumourcells 
after pre-lncubatlon >8 weeks 
with Id and ld~ serum 
IF on autologous cells, 
Monocytes, Granulocytes, 
Platelets and Erythrocytes 
Tissue distribution by 
IP staining on frozen tissue sections 
4. Ascites production 2-4 months 
1n SPF BALB/c mice 
5. Sterile purification: 
precipitation (NH4)2S04 50X 
chromatography DEAE-52 
concentration 1 week 
ultra centrlfugatlon 
0.2U filtration 
6. Pyrogenldty test 1n rabbits 1 day 
7. Microbiol contamination control 2 weeks 
8. T H E R A P Y 
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for the production of antl-ld Is outlined In Figure 1. At the current stage of 
technology It takes about half a year before therapy can be started. In some 
cases this time Interval was too long, In one case the patient developed a 
paraprotein, which was not present at presentation. 
The frequency of antl-ld producing hybrids Is In the range from 0.1X to 15X. 
In general the Immunization with purified Id Is reported to give a better yield 
than Immunization with Id* cells [14,40,42], although de Rie et al [9] reported 
up to 9.2 X yield by Immunization with cells. The Immunization with Id* cells 
Is a more streamlined approach saving the time needed for the Idlotype 
purification. 
Although only a few patients from the group of В-cell malignancies can be 
considered for antl-ld therapy, the selection criteria used do not warrant a 
successful therapy, but are the minimal requirements for treatment planning. 
Several parameters may Influence the outcome of therapy depending on the 
characteristics of a particular tumour, the antibody used, and the clinical 
condition of the patient. In our studies we have analyzed several of these 
parameters. When we analyzed the s-Ig positive malignancies for their Isotype 
constitution and expression Intensity we found In general that the B-cell 
lymphomas showed higher Intensities than the B-cell leukemlas with few 
exceptions. These differences, however, were not predictive for the final 
outcome of antl-ld therapy. Therapy of patient DEF (B-CLL with low Id 
expression, ± 6,000 Id/cell chapter 2) resulted In a significant tumour-reduc­
tion, Indicating that even with low target antigen expression Immunotherapy 
can be effective. 
The Ig production by the tumourcells In vitro varied from tumour to tumour, 
a phenomenon reported by others as well [26]. The In vivo circulating Id level 
did not correlate with the degree of Ig-productlon of the tumourcells In vitro, 
In several patients we found no detectable amounts of In vitro Ig producti­
on, whereas In vivo paraproteins were present (unpublished observations). 
We did observe changes In time of In vitro Id-production by the same tumour, 
In one case this was most likely due to selection, In another one It was due 
to differentiation, which explained very well the In vivo observations on 
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tumour mass and serum Id concentrations (chapter 5). 
In our studies the Idlotype modulation by Interaction with ant l - Ig was similar 
for all I g ' tumour B-cells, resulting In a decrease of s-Ig expression due to 
Internalization and shedding. When we compared the modulation of Idlotype 
with ant l- Ig and MoAb antl- ld on different tu-mours, the results with MoAb 
antl-ld were Identical to ant l - Ig (chapter 3,4). This enables the analysis of 
the modulation characteristics by ant l - Ig and Its consequences before MoAb 
anti-Id's are raised. In v i t ro modulation of Idlotype by MoAb antl- ld Is a 
common f inding. Absence of modulation, although exceptional, might occur due 
to Intra-ld crossllnklng Instead of Inter-Id crossllnklng by ant l- ld as 
described by Elliot et al [12]. In v i t ro the amount of antigen modulation Is 
time dependent (chapter 3,4). In vivo Idlotype modulation was observed when 
the clearance of opsonized tumourcells became less effective (chapters 2,3,4). 
According to the f indings of Elliot et al [12], all our MoAb anti-Id's are 
supposed to be Inter-Id crossllnklng MoAb's and therefore might have been 
capable In transducing antlgen-IIke signals, resulting In activation, prol i fe-
ration and /o r differentiation. The proliferative responses to the Interaction 
with ant l - Ig / ld have been described In chapter 5 and 6. Three response 
patterns were identif ied: enhancement, non responsiveness and Inhibition. The 
reaction appeared not to be correlated to the Immunophenotype, and therefore 
seems to be an Intr insic property of the malignant B-cell, most likely linked 
to the stage of differentiation. The changed characteristics of patient BOR's 
tumourcells (chapter 5), strongly suggest an MoAb anti- id Induced di f feren-
tiation. The antibody used for therapy stimulated the proliferation of the 
tumourcells In v i t ro. I t Is unknown whether In vivo the differentiation of the 
tumourcells Is due to the MoAb antl- ld Itself or to additional effect of the 
autocrine production of Interleuklns like TNFa (chapter 4), IL-1 to 6 and the 
Interferons. The latter suggestion Is supported by the f inding that BCGF I 
(IL-4) Induced the expression of anti-gens as recognized by MoAb BoM22 on 
pre-therapy tumourcells (chapter 5), whereas the post-therapy tumourcells 
expressed these antigens "spontaneous! y " . I t was also questioned whether 
these proli ferative responses were Indicative for therapy outcome, which 
would have meant an additional selection criterium. Our f indings do not sup-
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port the supposition that B-cell tumours, which are sensitive to stimulation 
by MoAb anti-Id, have worse therapy outcome than those Inhibited or non 
responsive to MoAb antl-ld. Significant tumour reductions were established 
in patients DEF (±50*) and BOR (±90X), whereas patient DEF's tumourcells 
were suppressed and patient BOR's tumourcells were stimulated by MoAb 
antl-ld to proliferate. 
In the mouse It was demonstrated that the IgGj, Isotype Is more effective In 
Immunotherapy than IgG, and IgGjj, [22] and that the most Important effector 
mechanism for elimination of antibody coated cells Is represented by the 
mononuclear phagocyte system [19]. Within the Caucasian population the 
monocytes of only 70% percent of the people can mediate the mouse MoAb IgG, 
antl-CD3 Induced T-cell proliferation, for mouse IgG^lgG^ this Is +100% and 
for IgG2b It Is less than 10% [41]. The differences In reactivity for mouse IgG, 
and IgGjj/IgGj are due to the different Fc receptors, present on human 
monocytes [44]. All our patients were analyzed for the presence of functional 
FcR for mouse IgG,, IgG^lgG^ and IgG2 l lon monocytes by the FcR mediated 
T-cell mltogenesls as described by Tax et al [41]. Our findings were In 
agreement with the data obtained from healthy Individuals: 100% FcR I+, 70% 
FcR I I + and so far no FcR for mouse IgG^. From the patients we treated with 
MoAb antl-ld, patient DEF and BOR were FcR I I hlgh-responders (chapters 
2,3,4). They were treated with IgG, MoAb antl-ld. Patient HUS was a FcR I I 
low-responder, he was treated with an ІдСз MoAb antl-ld. Most Immunotherapi­
es have been performed with IgGj, MoAb's, however those carried out with an 
IgG, or IgGjb antibody have been proven to be very effective as well (chapter 
2,3,4) [27]. The complete remission of a B-cell lymphoma was obtained with an 
IgGji, MoAb antl-ld [29]. A clear superiority of a specific mouse Isotype for 
Immunotherapy In man has not been demonstrated. Van de Winkel et al [45] 
demonstrated that proteolytic enzymes could turn low responder FcR I I Into 
high-responder FcR I I . Micro environmental proteolytic activity Is very likely 
to occur In vivo and so a "non responder" patient may also benefit from 
treatment with an IgG, MoAb. The FcR I I is also present on granulocytes and 
platelets [25,34]. Graziano et al [16] demonstrated that FcR I I on granulocytes 
and monocytes are capable to mediate cytotoxicity. Due to the FcR I I , the 
granulocytes may be recruited to exert their effector cell potential on IgG, 
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opsonized target cells, whereas the platelets are recruited for the clearance 
of IgG1 containing Immunecomplexes (chapter 2,3,4). Therefore IgG| MoAb's 
might be even better candidates for Immunotherapy than IgGjj/IgGj MoAb's. 
Table I. Pre-lmmunotherapy observations on some parameters. 
Parameters 
1d Isotype 
1d expression 
1d secretion 
MoAb ant1-1d 
1nduced: 
1. modulation 
2. proliferation 
Monocyte FcRII 
DEF 
μ,δ,γ,α,Κ 
++ 
++ 
+ 
Inhibition 
HR 
HUS 
μ,δ,ί 
+++ 
+ 
+ 
no 
LR 
BOR 
μ,δ,Κ 
++++ 
+ 
+ 
enhancement 
HR 
HR: High responder type FcRII. LR: Low responder type FcRII. 
In Table I the parameters, determined in v i t ro, are summarized. In Table I I 
the effects are summarized for the patients we treated with MoAb anti-Id. We 
and others [17,27,32] have shown that Immunotherapy with MoAb ant l- ld, with 
doses up to 1000 mg/day, were tolerated very well. Only minor and transient 
side effects were observed, without the necessity of Interruption of the 
medication. Severe signs of serumslckness, likely to occur when circulating 
Immunecomplexes are present, were not observed, despite significant amounts 
of circulating Immunecomplexes. Liver and kidney functions remained stable. 
Thrombocytopenia has been observed mostly In patients with circulating 
Idiotype [27, chapter 2,3,4], treated with IgG, MoAb's. I t could be tempered by 
adaptation of the Infusion rate (chapter 2). I t no longer occurred, as soon as 
the idiotype was cleared from the circulation (chapter 2,3,4), Indicating the 
thrombocytopenia to be Immune complex mediated. The thrombocytopenia may 
be a FcR I I mediated event. I t was demonstrated by Looney et al [24] that 
the FcR I I on thrombocytes and monocytes exhibit Identical patterns In Iso-
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Table I I . Observations during MoAb antl-ld therapy. 
Parameters 
MoAb ant1-1d 
Peak dose 
Cumulative dose 
Therapy days 
Period 
Id clearance 
Serum peak MoAb 
antl-ld 
Id "resynthesls" 
Serum Immune-
complexes 
Complement : C3 
consumption C4 
fB 
Thrombocytopenia * 
MoAb antl-ld bin­
ding to tumour 
Id modulation 1n 
vivo 
Tumour reduction 
Ant1-mouse 
response 
Side effects: 
- fever 
- oedema 
- chills 
- vomiting 
- tightness 
- muscle pain 
- diarrhoea 
Organ functions 
Patient DEF 
IgG1 
1,000 mg 
24,500 mg 
4 χ 18 
1 year 
+ 
10 mg/l 
++ 
yes 
+ 
++ 
± 
yes 
yes 
yes 
±50% 
no 
minor 
+ 
+ 
+ 
-
+ 
-
-
normal 
Patient HUS 
IgG3 
830 mg 
4,500 mg 
6 ι 1 ι 1 
9 days 
+ 
44 mg/1 
+++++ 
yes 
+ 
++ 
± 
no 
no 
·> 
no 
no 
minor 
-
+ 
-
-
-
+ 
-
normal 
Patient BOR 
IgGI 
83 mg 
770 mg 
3x5 J 3x1 
6 weeks 
+ 
2.2 mg/1 
+ 
yes 
?# 
?# 
?# 
yes 
yes 
yes 
±90X 
no 
minor 
+ 
-
+ 
+ 
-
-
+ 
normal 
#) concentrations Increased during therapy. 
*) only occurring during Idlotype clearance. 
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electric focusing analyses (IEF) within an Individual. Polymorphism for FcR 
I I was reflected in IEF, correlating with responder and non responder FcR I I 
on monocytes. This polymorphism may explain why thrombocytopenia did not 
occur In all patients, with circulating Idlotype and treated with an IgG1 MoAb 
antl- ld. 
Granulocytopenia was observed also [27] and may be explained by a similar 
FcR II/FcR Ш mediated mechanism. However our observation on TNFa 
suggests the possibility for an additional explanation (chapter 4). The 
crossllnklng of monocyte FcR, provoked by Immunecomplexes and/or opsonized 
particles, Induces the production of TNFa [8]. TNFa activates endothelial cells 
to express adhesion molecules for lymphocytes [35]. Besides, the production 
of IL-1 is induced, which causes the endothelial cells to express adhesion 
molecules for granulocytes [7,35]. In this way lymphocytes as well as 
granulocytes could become attached to the endothelium explaining the fall In 
leukocyte counts by a shift to the marginal pool. Similar f indings have been 
described In mice after exogenic administration of TNF [33]. 
Although we did not observe an anti-mouse Immuneresponse in our patients, 
It has been reported on by others [11,27,30,37,38]. Anti-mouse Immuneresponse 
makes f u r t h e r therapy useless. The reason that our patients did not develop 
an anti-mouse Immuneresponse may be due to tolerance induction by high 
doses of MoAb. Sears et al [39] observed that 8 out of 9 patients, treated 
with single doses -less than 200 mg - of MoAb 1083-17-1A, against colorectal 
cancer, developed an anti-mouse Immunereponse, whereas 8 out of 9 patients 
receiving doses over 200 mg did not develop an anti-mouse immuneresponse. 
Two of our patients did have CLL and in these patients the lack of an ant i-
mouse Immuneresponse could be related to an Impaired humoral Immunerespon­
se. 
Only once the treatment with MoAb antl-ld resulted In a complete remission 
[29], however most treatments did cause temporary tumour reductions 
[5,17,18,27,32]. The fact that most patients treated In th is way were not res­
ponsive to conventional therapies anymore, Indicates the potential of this kind 
of therapy. The mechanism Is most l ikely, that tumour-speclflc antibodies o p -
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sonlze their targets causing Fc-FcR Interactions with Immune-effector cells, 
resulting In the activation of the Immune system and the production of all 
kinds of leukocyte factors with plelotroplc effects, like the Interleuklns, the 
Interferons and complement components. The capacity of the Immune-effector 
system and the Immune-regulatory system are crucial In the outcome of 
therapy. Lowder et al [26] found a correlation between the outcome of therapy 
and the number of tumour Infiltrating mature T-cells (CD3+,CD4+) before anti-
Id therapy, suggesting the préexistence of a host-tumour Interaction. Miller 
et al [29] observed In their remarkable successful antl-ld treated patient, that 
the tumour continued to regress after the period of antl-ld administration, 
suggesting the Involvement of the Immune-regulatory system besides the 
MoAb mediated Immune-effector system. An additional explanation for the 
former finding Is, that a sufficient number of Immune-competent cells must be 
present to be able to cope with the amount of tu mou reel Is. In most patients, 
treated with antl-ld, bone marrow was Infiltrated by tumourcells, which may 
have caused bone marrow suppression, causing effector-cell shortage and 
finally resulting In therapy failure. This was not the case for the patient with 
a complete remission [26,29]. 
I t is quite evident that the final outcome of Immunotherapy with MoAb antl-
ld is determined by numerous parameters, which can be divided Into: 
Tumour related parameters like: 
Tumour-mass, circulating Idiotype, tumour clonality, Idlotype expression, 
Idlotype mutation, and Idlotype modulation. 
Antibody related parameters like: Isotype of the MoAb, affinity, epitope 
specificity (Inter- or Intra-ldlotype crossllnklng [12]), In vivo half-life. 
Patient related parameters like: capacity and condition of the Immune-effector 
system, antl-mouse immuneresponse, the presence of functional Fc receptors 
for mouse Ig on Immuno-competent cells. 
The therapy with MoAb antl-ld Is Just the beginning of an Investigation In the 
field of Immunotherapy with MoAb's. MoAb antl-id therapy has proven to be 
tolerated very well. The next goal should be to Improve the applicability and 
efficacy of Immunotherapy with monoclonal antibodies and to achieve comp-
lete cures In selected cases. 
Θ6 
With respect to the treatment of B-cell malignancies with MoAb antl-ld 
Improvements could be: 
Simplification and acceleration of the antl-ld production. 
Cocktails of MoAb's with respect to Isotypes, specificities and affinit ies. 
Additional modification of MoAb's Into mouse χ human chimeric antibodies 
using the human Fc fragment [18], F(ab') fragments [15] or heterocon-
jugates [21]. 
The use of MoAb's In f i r s t line therapy In patients with l i t t le tumour mass 
and good clinical condition. Most patients treated with MoAb antl-ld were 
patients at end stage of disease with massive tumour. 
A controlled MoAb administration by a careful monitoring of the Immune-
effector system, to avoid exhaustion of the latter. 
Treatment with MoAb's of residual disease after tumour reduction with 
conventional therapies. 
Combination therapies with biological response modifiers like Interleuklns 
and Interferons. Evidence Is accumulating In favor of combination 
therapies: Synergistic effects of antl-ld treatment In combination with I L -
2 [3,4] and IFNa [2] In a murine lymphoma has been demonstrated, and 
also In man the combination of IFNa and MoAb antl-ld was reported to be 
effective [6]. 
An alternative for antl-ld therapy Is the antl-B-cell therapy. B-cell specific 
antigens like CD19 and CD20 provide promising targets for the Immunother­
apy of B-cell malignancies. Antl-CD19/CD20 antibodies could be used for Im­
munotherapy of almost any B-cell malignancy, except for the myelomas, which 
do not express CD19/CD20 antigens. Furthermore antl-CD19/CD20 will eliminate 
normal B-cells as well, which may prevent anti-mouse Immuneresponse. MoAb 
antl-CD20 turned out to be effective In tumourcell elimination [31], In vivo no 
antigen modulation could be demonstrated, the Ideal candidate for "conventio­
nal" Immunotherapy. In contrast MoAb antl-CD19 does Induce considerable 
antigenic modulation [10,43], but because the complex Is mainly Internalized 
this target-antigen could be a candidate for Immunotoxlns. However the use 
of antl-B-cell antibodies lacks the tumour-speclflclty and probably the 
possibility to reconstitute the Idiotype antl-ld regulatory network [20] which 
Is most likely necessary for maintenance of remission [29]. On the other side 
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the number of patients, who can be treated, is considerably Increased. 
Besides an antl-B-cell therapy followed by treatment with either antl-ld or Id 
to manipulate the Id antl-ld network would be a very Interesting approach. 
In conclusion It seems worthwhile to Investigate and exploit f u r t h e r the 
potentials of Immunotherapy of cancers, to which the f indings described In 
this thesis may have added some contribution. 
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SUMMARY 
Although the conventional cancer therapies have been Improved considerably 
during the last decades, toxic effects on non-tumour tissues, temporarily as 
well as Irreversibly, cannot be avoided. With the Introduction of the 
Hybrldoma technique, a new approach became available: Immunotherapy with 
monoclonal antibodies, directed specifically against tumourcells. 
In this thesis the application of monoclonal antl- ldlotypic antibodies for the 
therapy of B-cell malignancies Is described, as well some parameters that may 
influence the final outcome of this kind of therapy. 
The B-cell malignancies express, exceptionally, a t ru ly tumour-speclflc marker, 
the Idlotype, that can function as a target for Immunotherapy with monoclonal 
antibodies (chapter 1). Three patients were treated by antl- ldlotypic 
antibodies (chapters 2,3,4,8). In two patients significant temporary tumour 
reductions were obtained, with Improvements In quality of life. These 
therapies clearly showed the potential of Immunotherapy with monoclonal an t l -
ldlotypic antibodies, because these patients had become resistant against 
conventional chemotherapy, pr ior to Immunotherapy. No severe signs of 
serumslckness were observed, only minor temporary side effects were 
experienced by the patients, which never made an Interruption of therapy 
necessary. I t was furthermore demonstrated that the mouse Ig subclass IgGj 
Is very effective In eliminating tumourcells and circulating Idlotype. The 
elimination of circulating Idlotype by IgG1 antl- ldlotypic antibodies seems to 
be platelet-FcRII mediated and Is accompanied by complement consumption 
(chapter 2,3,4). Elimination or destruction of tumourcells by IgG1 an t l -
ldlotypic antibodies Is, In part, mediated by the mononuclear phagocyte 
system. The f indings In this thesis (chapter 4) Indicate, that the activation 
of the complete cellular effector system Is Induced (Monocytes.Granulocytes.T-
cells) as well as the production of cytotoxic Interleuklns like TNFa. 
The causes, responsible for the ultimate therapy failures, are ascribed to 
tumour-, antibody- and patient-related parameters (chapters 3,5,7) like: an t i -
Id mediated tumour selection; tumour cell differentiation; exhaustion of the 
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effector system; extensive tumour masses and high concentrations of circulat-
ing Idlotype. 
The crossllnklng of Idlotype on tumour B-cells by either antl-Ig or antl-
Idlotyplc antibodies may result In heterogeneous proliferative responses of 
the tumour B-cells (chapter 6), which appeared to be a T-cell Independent 
Intrinsic property of the malignant B-cell and not predictable by phenotyplc 
analyses. The supposition that stimulation by antl-ldlotypic antibodies may 
be a contra-lndlcatlon for Immunotherapy with antl-ldlotypic antibodies Is not 
confirmed by the data described In this thesis (chapter 4,5). 
Therapy with antl-ldlotypic antibodies has proven to be very effective and 
to be tolerated very well. The next goal should be to Improve the applicability 
and efficacy of Immunotherapy of B-cell malignancies with monoclonal 
antibodies, which may be antl-ldlotypic and/or antl-B-cell. 
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SAMENVATTING 
Gedurende de laatste 20 Jaar heeft de therapie van kanker een sterke 
vooruitgang geboekt. De huidige conventionele behandelingen geven goede 
resultaten te zien. De nadelige effecten, zowel t i jde l i jke als permanente, van 
radio-therapie en chemo-theraple op normaal weefsel zi jn aanzienlijk terug 
gebracht, maar nog steeds onvermijdeli jk. Met de Introduktle van de 
hybrldoma technologie kwam een nieuwe vorm van kanker therapie beschik-
baar: Immunothérapie met monoclonale antistoffen. Hierbij wordt gebruik 
gemaakt van antistoffen opgewekt In muizen, specifiek gericht tegen de te 
behandelen kanker. 
In dit proefschrif t wordt de toepassing van monoclonale antistoffen be-
schreven en de factoren die het resultaat van deze toepassing beïnvloeden. 
Het betreft antistoffen gericht tegen tumoren van een bepaald type lympholde 
cellen, de zogenaamde B-cellen (normaal zelf verantwoordelijk voor de 
produktle van antistoffen tegen binnen gedrongen ziekte verwekkers). Deze 
B-cel tumoren brengen een bepaald kenmerk tot expressie, het Idlotype, dat 
specifiek Is voor elke B-cel tumor afzonderli jk en dus ook specifiek voor 
ledere patient met een dergelijke tumor. Dit Idlotype kan als doelwit dienen 
voor de monoclonale anti-stoffen, de antl-ldlotyplsche antistoffen (hoofdstuk 
1). 
Drie patiënten zi jn behandeld met antl-ldlotyplsche antistoffen (hoofdstukken 
2,3,4,7). BIJ twee patiënten werden, t i jde l i j k , omvangrijke tumor reduktles 
verkregen, tesamen met een verbetering In de kwaliteit van leven. Omdat de 
patiënten voorheen niet meer met conventionele therapieën te behandelen 
waren, b l i j k t hieruit dat deze Immunothérapie zeer effectief kan z i jn. 
Bovendien werden geen ernstige bijverschijnselen waargenomen. De 
bijverschijselen, die zich voordeden, waren gering en t i jde l i jk van aard en 
noodden niet tot staking van de therapie. Voorts Is gebleken dat mulze-
an tl stoffen van de IgG, subclasse zeer effectief z i jn In de eliminatie van tumor 
cellen en In het bloed v r i j circulerend Idlotype. De eliminatie van circulerend 
Idlotype door IgG, antl-ldlotyplsche antistoffen l i j k t bewerkstelligd te worden 
middels de Interactie met receptoren (FcRII) op bloedplaatjes en gaat 
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vergezeld met een verbruik van serum complement (hoofdstukken 2,3,4). De 
eliminatie of destructie van tumor cellen vla deze IgG, antl-ldiotyplsche 
antistof verloopt deels vla het mononucléaire phagocyten systeem. De 
bevindingen, zoals In dit proefschrift beschreven, geven aan dat een actlvatle 
plaats vindt van het totale cellulaire effector systeem (Monocyten, Granulo-
cyten,T-cellen) en dat daarnaast ook de produktle van cytotoxlsche Inter-
leuklnen zoals TNFa geïnduceerd wordt. 
De oorzaken voor het uiteindelijk mislukken van de therapie met monoclonale 
antl-ldlotyplsche antistoffen worden toegeschreven aan tumor-, antistof- en 
patlent-gerelateerde factoren (hoofdstukken 3,5,7) zoals: antl-ld gemedleerde 
tumor selectie; tumor cel differentiatie; uitputting van het effector systeeem; 
de uitgebreidheid van de tumor en de hoge concentraties van vrij In het 
bloed circulerend Idlotype. 
De Interactie van het Idlotype op de tumor cellen met antl-ldlotyplsche 
antistoffen kan resulteren In een verhoging of een verlaging van dellngs 
activiteit van de tumor cellen (hoofdstuk 6). Dit bleek een eigenschap van de 
tumor B-cel zelf en niet van eventueel aanwezige andere lympholde cellen. 
Bovendien bleek geen correlatie te bestaan met phenotypische kenmerken van 
de tumor cellen. De veronderstelling dat stimulatie, door antl-ldlotyplsche 
antistoffen, van tumor cellen tot een verhoogde dellngs activiteit een contra-
Indicatie voor therapie zou kunnen zijn wordt niet door de, In dit proef-
schrift, beschreven bevindingen bevestigd (hoofdstukken 4,5). 
De behandeling van B-cel tumoren met antl-ldlotyplsche antistoffen heeft 
bewezen zeer effectief te kunnen zijn en wordt bovendien zeer goed 
verdragen. In de toekomst zou het onderzoek zich moeten richten op de 
verruiming van toepasbaarheid en vergroting van werkzaamheid van de B-
cel tumor therapie met monoclonale antistoffen. 
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STELLINGEN 
behorende b i j he t p r o e f s c h r i f t : 
Immunotherapy of B-cel l malignancies with 
monoclonal anti—idiotypic antibodies. 
Het r e s u l t a a t van immunothérapie met monoclonale a n t i - i d i o t y p i s c h e 
cinti ^to-f-fen i s mede a-fhanl· f l i.H van een goed - funct ionerer id e-f-fector 
•ivslreem. E'en deTgeli.il· e t h e r a p i e moet daarom m e t a l s l a a t s t e 
redrruddel wnr ' len tneqepaï-t:, maar in een v roeq s tad ium van de z i e k t e . 
D i t pr-oM-f « c M r - i -f t 
De angst voo r een e r n s t i g e vorm van serumziel· t e t e n gevo lge van 
a n t i - i d i o t y p e t h e r a p i e geïnduceerde immuuncample;:en i s ongegrond. 
D i t p r - o e * » c t n i - l - f t 
Thrombocyt pn l· unnen een bel¿<ngri it-e r o l spe len b i j de k l a r i n g van 
immi uincomplexen. 
D i t p r - o » f a c b r - l - F t 
MUIR Igtì l a n t i - i d i o t y p i s c h e ant isto- f - fen b innen zeer e-f- fect ief een 
e l i m i n a t i e u i t de c i r c u l a t i e . bew^rl· s t e l l i g e n van zowel i d i o t y p e 
p o s i t i e v e ce l l en a l s v r i j c i r c u l e r e n d i d i o t y p e . 
D i t pr -oa- f а с Ь г - 1 - f t 
Een vermeende s u p e r i o r i t e i t van muis IgG2a ant isto-f-fen v o o r t o e p a s ­
singen in immunothérapie wordt i n de p rak t i j l · n i e t b e v e s t i g d . 
D i t p r - o v - # « c b r - l * t 
Een s t i m u l a t i e van de tumor ce l p r o l i f e r a t i e in v i t r o onder i nv loed 
van a n t i - i d i o t y p i s c h e a n t i s t o f f e n i s geen c n n t r a - i n d i c a t i e voo r im-
munothérapie met a n t i - i d i o t / p i s c h e a n t i s t o f f e n . 
D i t p r - o · * a c M r - l -f t 
7. De w i j ze waarop, b i j de e e r s t beschreven p a t i e n t met een succesvo l l e 
a n t i - i d i o t y p e t h e r a p i e , tumor r e g r e s s i e r e s u l t e e r d e i n een complete 
rem iss ie en he t - fe i t da t na 6 j a a r deze l fde i d i o t y p e p o s i t i e v e tumor 
r e c i d i v e e r d e , s u g g e r e e r t da t n i e t tumor e l i m i n a t i p maar immuun— 
r e g u l a t i e van doo rs lag gevende betel· ems i s voo r de handhaving van 
een complete rem iss ie . 
M i l l e r - a t « 1 . N . E n g l . J . Mmtí. 1 Ф В 2 | З О Д і 9 1 7 
B r o w n вЪ « 1 . B l o o d 1<?Β9| 7 3 , ^ 9 1 
8. Wanneer tumor Б—cellen gebruil· t worden a l s model v o o r h e t o p l o s s e n 
van v r a n g s t u l · l· en bt'tre-f-fende de i m m u u n - r e g u l a t i e van normale Ei­
c e l l e n z i j n de r e s u l t a t e n b i j v o o r b a a t a a n v e c h t b a a r . D i t zel-fde g e l d t 
v o o r h e t omgekeerde. 
•?. De benaming monol· l o n a a l a n t i - i d i o t o o p i s gezien h»t i d i o t n n p s p e c i f i e -
[ e k a r a L t e r van een т о п о П о п а І г a n t i s t o f c o r r e c t e r dan de benaming 
monol· l o n a a l a n t l - i d i o t y p e . 
10. Het t r a n s f u s i e e f f e c t op t r a n s p l a n t a a t o v e r l e v i n g i s mogelij l · t o e t e 
s c h r i j v e n aan de i n d u c t i e van a n t i - i d i o t y p i s c h e a n t i s t o f f e n . De t n t 
d u s v e r g e h a n t e e r d e d e t e c t i e methode l a a t een de'rqeli j l · e inter— 
p r e t a t i e t o e , maar l e v e r t geen c o n c r e e t b e w i j s v o o r de aanweziqrif?¡d 
van a n t i - i d i o t y p i s c h e a n t i s t o f f e n . 
R a a d o t » 1 . T * - « r t * p l . P r - o e . I < ? a 9 | 2 7 i 7 3 s 
B o c l u — P a c a a « a l . P r - o c . N a t . A c a d . a d . U S A 1 < ? Β 3 | Β 0 | 0 3 0 
11. Het door de t h a n s d e m i s s i o n a i r e r e g e r i n g g e v o e r d e m i l i e u b e l e i d i s 
geen b e v e s t i g i n g van de zegswi jze " Regeren i s V o o r u i t z i e n " . 
12. De l· oude k e r n f u s i e b l i j f t v o o r a l s n o g een h e e t t w i s t p u n t . 
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